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1. Introduction 
This paper provides a summary of the RNA interference mechanisms, from the 
beginning till today. All the great discoveries, the smaller successes, as well as 
the drawbacks of the past couple years are put together to build a whole picture 
of the effect. 
Already the fact, that the discovery of the RNA interference mechanism has 
been less than two decades ago, and the new technology got adopted already 
quickly in labs around the world and is used nowadays as a standard tool in the 
genetic-tool-box, shows how important this mechanism is [HOWARD, 2003] 
[SUGIMOTO, 2004]. RNA interference has the power to connect forward and 
reverse genetics, which implicates the direct link of biological functions and 
gene sequencing [CHANG et al., 2005].  
C. elegans developed into the model organism of choice, when it comes down 
to RNAi approaches in the first years. This is based on the perfectly timed 
coincidence of sequencing the genome of C. elegans and the finding of the 
Interference effect [SUGIMOTO, 2004]. Not only was the silencing effect 
discovered first in the worm, also the first microRNAs, including their function in 
regulation of developmental timing were discovered in the worm [FISCHER, 
2010]. More and more details of the mechanism were identified, such as an 
RNAse III enzyme called dicer, which cleaves long double-stranded RNA into 
one of the main players of the silencing effect called small-interfering RNAs, the 
knock-down mechanism linked with the microRNA pathway, and the discovery 
and the identification of some parts of the effector complex referred to as RNA 
induced silencing complex [COUZIN, 2002] [AGRAWAL et al., 2003]. Through 
this expanding information and the identification of the machinery of RNAi, 
every step of a whole physiological pathways and its function can be explored 
[LEUNG & WHITTAKER, 2005]. 
With the knowledge of the potency and specificity, the easy handling, and the 
possible application into mammalian cells, big hopes arose for developing new 
therapeutic agents or even individualized therapy [SEMIZAROV et al., 2003] 
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[PADDISON et al., 2002]. By a short review of knocking out the reduced folate 
carrier of the model organism C. elegans, it will be shown that this tool can also 
be maintained in nutritional research. 
Till today, the complete mechanism with all players and co-factors is still not 
unrevealed und further research will be necessary to be able to see the 
complete picture [SHAN, 2010].  
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2. The different terms 
A whole group of different but closely related phenomena represent a 
conserved ancestral process [MELLO & CONTE JR., 2004]. RNA interference 
(RNAi) in animals, post-transcriptional gene silencing (PTGS), co-suppression, 
and virus-induced-gene-silencing (VIGS) in plants, and quelling in fungi 
describe similar effects. Today, all of them are referred to as RNA silencing 
[PLASTERK, 2002]. All of them provide sequence-specific degradation of 
homologous messenger RNA, are indicated to function in different regulation 
pathways, share some homologous genes, like ego-1 in C. elegans, sde1 in 
Arabidopsis t., and qde-1 in Neurospora crassa, but they appear phenotypically 
different [CATALANOTTO et al., 2000] [AGRAWAL et al., 2003] [COGONI & 
MACINO, 2000]. 
 
2.1 Homology-dependent gene silencing 
Homology-dependent gene silencing (HDGS) describes a silencing 
phenomenon of homologous nucleic acid sequences. It can occur either at the 
transcriptional level through a higher number of promoter methylations, or at the 
post-transcriptional level in the cytoplasm, through degradation of the 
complementary sequence (target) to the trigger [KOOTER et al., 1999]. This 
term HDGS, summarizes many homology-dependent silencing mechanisms 
including RNAi, co-suppression, VIGS, and quelling [PADDISON et al., 2002].  
 
2.2 Transcriptional gene silencing  
In transcriptional gene silencing (TGS), like the name already explains, the 
silencing effect occurs at the transcriptional level through methylations of the 
promoter sequences. Compared to post-transcriptional gene silencing, TGS is a 
stable change of the genome and as a result of this alterations, it is heritable 
into the next generations [HANNON, 2002].  
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2.3 Post-transcriptional gene silencing 
Post-transcriptional gene silencing (PTGS) was first discovered in plants. It is a 
natural silencing mechanism that is activated by viruses, mobile genetic 
elements such as transposons or transgenes, and is implicated in gene 
regulation in a variety of biological processes [SIJEN & KOOTER, 2000] 
[COGONI & MACINO, 2000]. PTGS has the ability to spread through the 
organism and can also be seen in the progeny [BASS, 2000]. 
 
2.4 Virus-induced gene silencing 
Post-transcriptional gene silencing triggered by viruses is referred to as virus-
induced gene silencing (VIGS) [COGONI & MACINO, 2000]. Some of the 
viruses developed strategies to inhibit the process, so that they can escape the 
degradation. VIGS is not heritable, but has, like PTGS, the ability to spread 
through different tissues [BERNSTEIN et al., 2001] [PLASTERK, 2002]. 
 
2.5 Co-suppression 
Co-suppression is related with RNAi; both use some of the same gene 
products, both act either post-transcriptionally or transcriptionally, both are 
implicated in transposon silencing, but they are not identical [GRISHOK, 
2005b]. For example in contrast to co-suppression, RNAi has the ability to 
spread in C. elegans [KETTING et al., 2003]. Co-suppression represents the 
possibility to reduce the expression of both, the introduced transgenes and their 
homologous endogenous gene, and was first discovered in petunia [TUSCHL, 
2001] [BERNSTEIN et al., 2001]. The co-suppression phenomenon in 
Neurospora crassa is called quelling [COGONI & MACINO, 2000]. 
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2.6 RNA interference 
RNA interference (RNAi) is a widespread phenomenon and is emerged in 
organisms ranging from plants, fungi, insects to mammalian. The term is 
normally used to describe the degradation of homologous messenger RNA 
triggered by double-stranded RNA [KETTING et al., 2001]. 
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3. RNA interference - mechanism 
RNA interference is an evolutionarily conserved gene silencing phenomenon 
[SIJEN et al., 2001]. The RNAi effect is not a phenomenon restricted to one 
organism, like the first assumption was. It was pointed out to work in a variety of 
organisms, such as plants, nematodes, protozoa, and insects and later also in 
vertebrates [CAPLEN et al., 2001]. First it was suggested, that RNAi works only 
at the post-transcriptional level. But now, evidence shows, that RNAi works 
post-transcriptionally (degradation of mRNA) as well as transcriptionally 
(suppression of the transcription) [AGRAWAL et al., 2003]. 
After years of research, it is proved that RNA interference and other silencing 
phenomena like PTGS, quelling, co-suppression are closely linked and related 
to each other [ELBASHIR et al., 2001b]. All mechanisms require some related 
proteins and use some parts of each other’s pathway [ZAMORE, 2002]. The 
phenomenon is referred to RNAi because of the function. After injection of 
double-stranded RNA (dsRNA) into the cell/tissue, a highly specific silencing of 
the complementary sequence to the introduced dsRNA is displayed [ELBASHIR 
et al., 2001b]. After the recognition of dsRNA, chemically synthesized small 
interfering RNAs (siRNAs), endogenous expressed siRNAs, or microRNAs 
(miRNAs), a complementary-dependent degradation of the target mRNA gets 
started [LEE et al., 2006]. This degradation results in the absence of the 
cytoplasmic transcript of the target or more exactly, only a very low level can be 
measured, because the accumulation of the normal cytoplasmic concentration 
was disturbed. Due to the fact that the nuclear gene expression was still 
working, and not perturbed at all, the degradation step was placed into the 
cytoplasm [COGONI & MACINO, 2000]. In some organisms it is possible that 
the effect gets inherited to the next generation, but it is important to mention, 
that there are no genetical changes of the genome involved KETTING et al., 
2003]. RNA interference is a mechanism which is dependent on the 
concentration of the trigger molecule and is temporarily limited [TIMMONS et 
al., 2003]. This ancient, but newly discovered mechanism made rapid gene-
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function analysis possible; first in worms and flies and afterwards also in 
mammalian cells [ZAMORE, 2001].  
 
Fig. 1 RNAi-mediated gene silencing. 
Through processing of either long dsRNA, plasmid-based shRNA, or endogenous miRNA by an RNAse
III enzyme dicer, the RNA gets cleaved into smaller fragments (siRNA), with the characteristic 2-3nt 3’
overhangs and the 5’ phosphate group. In contrast, the synthetic siRNA is converted in the active form
by an endogenous kinase. Small interfering RNAs associate with RISC to guide the mRNA cleavage. In
general, the strand with the lower stability at the 5’ end enters preferred RISC. An RNA with a perfect
match to the target RNA act like a siRNA and results in mRNA degradation, and RNA with a partial
match works as an miRNA and results in translational repression. [MITTAL, 2004] 
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3.1 Discovery of RNA interference 
RNA interference is one of the most important discoveries in the last century, 
and was honored with the Nobel Price for physiology or medicine in the year 
2006 [Nobelprize.org, 2011]. 
 
„RNAi itself is at least one billion years old. Biological mechanisms 
are far more constant than the positions of continents on our planet” 
[MELLO, 2007]. 
 
For long time, it seemed that RNAs act only 
as messengers and possess catalytical, 
structural, and information decoding function 
in the biogenesis of proteins. But with the 
discovery of RNAi and the growing 
knowledge of the mechanism, the picture 
changed, and it got more and more 
complicated [NOVINA & SHARP, 2004]. 
Silencing of an endogenous gene was 
discovered by accident. Introduction of 
transgenes in purple petunia plants, with the 
intention to make the flower darker purple, 
resulted in white or patchy plants. There was 
no expected over-expression of the color; 
both, the transgene and the expression of 
the endogenous gene were silenced. The 
observed phenomenon was termed co-
suppression. Co-suppression is widespread 
in the kingdom of plants, and can also be 
found in fungi, termed quelling. The ability of 
Fig. 2 Transgenic petunia flowers
Through supplementation of a chalcone 
synthase transgene, the purple 
pigmentation is rather suppressed than 
enhanced.  
modified from [NAPOLI et al.,  1990] 
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the silencing signal to travel long distances to other tissues of the plants was 
seen [COGONI & MACINO, 2000]. 
The mechanism was thought to act as a “primitive immune system” of the 
genome [PLASTERK, 2002]. The hypothesis that it must be an evolutionarily 
conserved, natural defense response against “parasitic” sequences was born 
[KOOTER et al., 1999]. 
RNAi arose to a powerful tool and one of the standard methods for silencing of 
gene expression in diverse organisms. It is a simple method for knocking-down 
the gene expression in diverse organisms. It started with expanding our 
understanding and knowledge at the whole genome level in Caenorhabditis 
elegans. The discovery of RNA interference in C. elegans and the completion of 
its whole genome sequence was a perfect coincidence [SUGIMOTO, 2004]. 
Andrew Z. Fire and coworkers published their first observations that introduction 
of either antisense or sense RNA into Caenorhabditis elegans were equally 
effective in inhibiting specific gene expression [ZAMORE et al., 2000]. 
Introduction of long double-stranded RNA was at least tenfold more efficient 
than the single-stranded sense or antisense RNA alone [HANNON, 2002]. The 
surprising result that both single-stranded RNAs work with the same efficiency 
could be figured out. They showed that neither purified sense nor antisense 
RNA could introduce any silencing effect. The potent trigger for the silencing 
effect resulted from double-stranded RNA. The solution of the puzzle was found 
in contaminations of the single-stranded RNA by double-stranded RNA 
[ZAMORE et al., 2000]. Craig C. Mello named the mechanisms after the 
observed silencing processes, RNA interference [FIRE, 2007]. 
Introduction of smaller and smaller amounts indicated that already a few 
molecules per cell, of double-stranded RNA, were efficient enough to initiate 
RNA interference. Not only that a few molecules per cell can trigger silencing, it 
was also seen that the silencing occurred in tissues in the entire body. The 
effect lasted up to several days, and in some cases it was inherited into the next 
generations [FIRE, 2007]. Because of those results, it was suggested that the 
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mechanism involves a catalytical and/or amplificational step [SIJEN & 
KOOTER, 2000].  
Phenotypes of null-mutants were created after injection of dsRNA [COGONI & 
MACINO, 2000]. Further research found an easier method to deliver dsRNA 
into the worm. It was found that feeding C. elegans with bacteria expressing 
dsRNA corresponding to unc-22 resulted in similar phenotypes like unc-22-
mutants [HUNTER, 2000]. Also soaking in a high concentrated dsRNA solution 
was efficient enough to induce the silencing phenomenon. Those efforts made it 
possible to perform large-scale genome-wide RNAi screens. From this point on, 
it was possible to search for all genes that are essential in diverse biochemical 
pathways like embryogenesis, longevity, apoptosis, and more [GOLDEN & 
O'CONNELL, 2007].  
The newly discovered phenomenon worked not only in plants and nematodes. It 
was also present in Arabidopsis thaliana, Xenopus laevis, Drosophila 
melanogaster, Trypanosoma brucei, Hydra magnipapillata, and zebrafish 
[BARSTEAD, 2001]. To find the mechanism also in mammalian cell lines, more 
time had to pass [ELBASHIR et al., 2001a]. Experiments suggested that the 
“core” mechanism of the silencing process is preserved in all those named 
species. So the evolutionarily ancient nature of RNA interference was 
uncovered and proved [SUGIMOTO, 2004]. Interestingly, there is no evidence 
for RNAi in archea and prokaryotes, so it seems that RNA silencing is an 
innovation from the eukaryotic organisms [ZAMORE, 2002]. 
The possibility that different small RNA classes could be the key to the RNAi 
process came from experiments in plant systems. A class of small RNAs, 
ranging in size from 21 to 25 nucleotides, was found. And it looked like they 
were closely related to the silencing mechanisms. Evidence showed that those 
small RNAs, referred to as small interfering RNAs, derive from the long double-
stranded RNA. Dicer, an RNase III enzyme cleaves the long dsRNA into these 
smaller fragments [FIRE, 2007]. Through cleavage, the important characteristic 
structures of the 5’ and 3’ end of siRNAs are generated [CAPLEN et al., 2001]. 
It was further suggested, that a multiprotein complex, later referred to as RNA 
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induced silencing complex (RISC) recognizes the complement mRNA and 
initiates the degradation [HUTVÁGNER & ZAMORE, 2002].  
A lot of research was done in those years, and a lot of discoveries were made. 
It got possible to inject successfully chemically synthesized siRNAs into 
mammalian cells, to induce the RNAi effect. The first successful approach was 
with embryo cells of mice [ZAMORE, 2001]. Furthermore vectors, employed as 
transfection vehicles, were invented, such as plasmid-based or viral-based 
vectors. Nowadays, these vectors are well integrated into the tool box for RNAi 
[SHI, 2003]. Also not only similarities were discovered, differences like 
introduction of long double-stranded RNA into mammalian cells, resulted in 
activation of non-specific dsRNA response such as apoptosis. Systemic RNA 
interference was only observed in plants and C. elegans. And the proposed 
amplification step, including the use of target mRNA as template, employment 
of RNA-dependent RNA polymerases (RdRPs), and generation of secondary 
siRNAs, was only seen in C. elegans [SUGIMOTO, 2004].  
New drugs and therapeutic agents can be developed, since the connection of 
genomics, proteomics, and functional genomics is provided through the 
knowledge of genome sequences of diverse species and the attribute of RNAi 
to investigate details of physiological processes and pathways [SCHEPERS, 
2005].  
 
3.2 Important milestones in the discovery of RNA interference 
1974, Sydney Brenner introduced the new model organism C. elegans 
[BRENNER, 1974]. 
1979, the Caenorhabditis Genetic Center (CGC) was founded [STIERNAGLE, 
1999 reprinted 2005].  
PTGS was first discovered through an experimental accident in the plant 
petunia in the late 1980s [LAI, 2003]. 
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1993, the first non-coding RNA (later called microRNA), lin-4 was successfully 
cloned [HE & HANNON, 2004]. 
In 1995, it was established that introduction of either antisense or sense RNA 
resulted in RNA-mediated interference [SUGIMOTO, 2004]. 
1998, Caenorhabditis elegans was the first multicellular organisms with its 
whole genome completely sequenced [KIM, 2001]. It was perfectly timed with 
the discovery, that injection of double-stranded RNA into nematodes, results in 
sequence-specific gene silencing, termed RNA interference by Craig C. Mello 
[DYKXHOORN et al., 2003] [FIRE, 2007]. 
Post-transcriptional gene silencing was established in 1999 as antiviral 
mechanisms in plants [PARRISH et al., 2000]. 
2000, the genome of Drosophila melanogaster was completely sequenced 
[KIM, 2001]. RNA induced silencing complex was purified in Drosophila cells 
[HAMMOND et al, 2000]. Let-7, a second microRNA was discovered in C. 
elegans, and it was shown that it is conserved in diverse bilaterian species [HE 
& HANNON, 2004]. RNA interference was successfully shown in mouse 
embryos [WIANNY & ZERNICKA-GOETZ, 2000]. 
2001, the human genome was completely sequenced [KIM, 2001]. The enzyme 
dicer was identified [COUZIN, 2002]. Small 21-23 nucleotide fragments, cleaved 
from long double-stranded RNA, seem to mediate RNA interference 
[ELBASHIR et al., 2001b]. During the year, the link between small interfering 
RNA and microRNA biogenesis was proved [LAI, 2003]. It was demonstrated 
that synthetic double-stranded siRNAs induce RNAi in different mammalian cell 
cultures, including HeLa cells [ELBASHIR et al., 2001a]. 
2002, it got possible to transfect siRNAs into the targeted cell through plasmid- 
or viral-vectors [SHI, 2003]. In the same year, it was discovered that 
approximately 1% of the metazoan genome encodes microRNAs, and proved 
their function in the regulation of gene expression [WADHWA et al., 2004].  
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For their discovery of the gene silencing method RNAi, by dsRNA, the Nobel 
Prize in physiology or medicine 2006 was awarded to Andrew. Z. Fire and Craig 
C. Mello [Nobelprize.org, 2011]. 
 
3.3 The natural role of RNAi  
RNA interference is not only a silencing mechanism, where corresponding 
messenger RNA is degraded by an RNA trigger. The mechanism emerged most 
likely as mechanism to protect the genome of invading elements, and works as 
an ancient immune system [DYKXHOORN & LIEBERMAN, 2005]. 
RNAi or more specific the “core” machinery of RNAi is linked with a lot of other 
natural functions, like antiviral response to invading viruses, protecting the 
genome against transposable elements, maintaining the stability of the genome, 
introduction of a non-specific interferon response, remodeling of chromatin 
structure, and regulation of gene expression and developmental programs, as 
well as cell differentiation and cell death [DYKXHOORN & LIEBERMAN, 2005] 
[KIM et al., 2005]. The whole picture is still not complete and more research will 
help to identify the missing parts [SHAN, 2010]. 
 
3.3.1 Ancient defense mechanism  
It is necessary for every organism to protect its genetic code against invasions 
by mobile genetic elements, such as transposons and viruses, and genetic 
modifications [ELBASHIR et al., 2001b]. It seems that RNA interference is the 
most ubiquitous and ancient antiviral system developed in plants as well as 
animals [SHARP, 2001]. The first assumptions that RNA interference and post-
transcriptional gene silencing might represent an ancient cellular defense 
mechanisms evolved already early. These assumptions are based on 
observations such as; first, viral RNAs can be targets for PTGS; second, a 
number of viruses evolved mechanisms to bypass the PTGS-reaction; third, 
through the spreading effect, from cell to cell, a systemic response is possible; 
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and fourth, plants without an effective PTGS response are more affected by 
some virus-infections [FIRE, 1999].  
Because double-stranded RNA is a key intermediate in the life-cycle of many 
viruses, and their ability to produce aberrant RNA, it is suggested that by 
generation of double-stranded RNA the defense mechanisms could be 
activated [FIRE, 2007] [TUSCHL, 2001]. Viruses might act as targets and 
inducers for the activation of the whole process, involving the generation of 
short dsRNA fragments by dicer, the cleavage and the destruction of the target 
RNA [TUSCHL, 2001] [MARTINEZ et al., 2002]. And indeed, confirmation was 
found. So far, for C. elegans, no natural viral pathogens are identified. By 
introduction of a mammalian pathogen called vesicular stomatitis virus (VSV) 
into the nematode, reliable defense mechanisms were detected. RNAi-deficient 
mutants display higher affinity for infections than the wild-type strain N2. Data 
also confirmed that some components of the RNAi pathway are involved, like 
RDE-1 and RDE-4. In addition, in RNAi-sensitive strains, rrf-3 and eri-1 
mutants, the percentage of infected cells were significantly lower than in N2 
[WILKINS et al., 2005]. Also observations, that some viruses are capable to 
inhibit the spreading effect through the plasmodesmata of the plant, and the 
discovery that some viruses encode proteins with the ability to suppress the 
PTGS phenomenon, to bypass the cellular immunity, and allow further viral 
replication, approved the early assumptions [BERNSTEIN et al., 2001] 
[WILKINS, 2005].  
In summary there is enough evidence of the ability of RNAi to function as 
defense mechanism against viruses and/or other selfish elements in simple 
organisms. But it might be possible that the antiviral effect of RNAi has been 
lost in mammals [FIRE, 2007]. 
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3.3.2 Transposon silencing and genome stabilization 
One key function for every organism is to provide the stability of the genomic 
sequence. Evidence showed us, that RNAi is employed to maintain the genomic 
stability [NYKÄNEN, 2001]. Transposons are endogenous selfish/parasitic 
mobile genetic elements with the ability to jump around within the genome. 
They either move as RNA sequences (retrotransposons) or as DNA fragments 
and integrate into the genome via replicative mechanisms or via a “cut-and-
paste” mechanism. Up to 45% of the human genome and 12% of the C. 
elegans genome is built by these mobile elements, and different numbers of 
copies are present in the cells [VASTENHOUW & PLASTERK, 2004]. It is 
important to regulate them strictly, because their activity can result in genome 
instability by acting as potential mutagens. They can provide potential sites for 
non-homologous crossover during DNA repair, as well as changed activity of 
gene functions can occur [BERNSTEIN, 2001]. At this point, RNA interference 
appears in the picture. It is possible that RNAi may play its part in the silencing 
of transposons. It was shown, that alteration in four genes, mut-1, mut-7, rde-2, 
and rde-3 lead to a decreased RNAi effect, but an increases mobilization of the 
mobile elements [TABARA et al., 1999]. One way to control the activity is to 
suppress the mobilization of transposons and the accumulation of repetitive 
DNA sequences in germline [ZAMORE, 2001]. Suggestions implicate RNAi as 
defense mechanisms against the accumulation of those mobile elements in the 
germline [TABARA et al., 1999]. Double-stranded RNA might act as trigger, or a 
second possibility, transposon transcripts (for example Tc1-transcripts) may 
serve as template for RdRPs resulting in double-stranded RNA, to induce 
transposon silencing. Afterwards a cleavage step by dicer might generate Tc1-
siRNAs, and the corresponding targets get destroyed [VASTENHOUW & 
PLASTERK, 2004]. It seems that transposon silencing in germline works mainly 
post-transcriptional [GRISHOK, 2005b]. 
It is an important fact to keep in mind, that transposon silencing is often counted 
as an RNAi phenomenon, but actually those two mechanisms are not identical, 
they only share some factors and their pathways converge [FISCHER, 2010].  
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3.3.3 Immune function 
It was early recognized that long double-stranded RNAs are very potent triggers 
of non-specific responses, especially activation of an interferon response in 
vertebrate systems [SHARP, 1999]. RNA silencing, especially triggered by 
dsRNA, can be seen as one part of an innate immune system against RNA 
viruses, transposable elements, and other double-stranded RNA invasions 
[MEISTER & TUSCHL, 2004].  
Long double-stranded RNA, at least 30 nucleotides in length, activates the non-
specific immune response [PADDISON et al., 2002]. As a result, an antiviral 
state of the cell is activated, which leads to a general shutdown of the protein 
synthesis of the affected cell [COGONI & MACINO, 2000]. The dsRNA-
dependent protein kinase (PKR) gets activated and further inactivates the 
translation factor eIF2α by phosphorylation. This results in an inactivation of the 
RNAi effect, translation, and protein synthesis and leads to the initiation of a 
non-apoptotic and apoptotic suicide program of the cell [CAPLEN et al., 2001]. 
To bypass this immune response, viruses developed a variety of skills to inhibit 
the activation of the PKR response [MONTGOMERY & FIRE, 1998]. 
 
3.3.4 Regulation of developmental timing 
The influence of RNA interference to regulate time developmental pathways is 
diverse. For example: dicer (dcr-1) mutants in C. elegans display various 
developmental phenotypes, including abnormal oocytes, inability to fertilize 
eggs, seam-cell production is altered, and a non-functional vulva which tends to 
burst. Lin-4 and let-7, both genes, encode small non-coding RNA fragments, 
which are involved in the developmental timing of C. elegans [BERNSTEIN et 
al., 2001]. Another gene, ego-1, is required for germline development and 
fertility in C. elegans [MAINE, 2001]. 
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3.3.5 Involvement in heterochromatin modification and methylation 
The first evidence was discovered in plants; afterwards also in fungi and 
animals, that co-suppression is linked with modifications in chromatin structures 
[BERNSTEIN et al., 2001]. It was suggested that RNAi influences also the gene 
expression at the chromatin level in various organisms [HANNON, 2002]. Years 
later, the RNAi mechanism was actually correlated with the chromatin regulation 
in fission yeast, and the important role of RNAi in heterochromatin silencing was 
established in all three kingdoms (plants, fungi, and animals) [MELLO & 
CONTE JR., 2004]. It was further discovered that modifications at the chromatin 
level by RNAi plays a part for the inheritance of the silencing signal [MELLO, 
2007]. Evidence was found, that via the RNAi mechanism, double-stranded 
RNA or rather small interfering RNAs are involved in chromatin DNA 
modifications and heterochromatic gene silencing [AGRAWAL et al., 2003]. It is 
now established that RNAi plays also an important part in the regulation of gene 
expression, chromosome behavior, and evolution [LIPPMAN & 
MARTIENSSEN, 2004]. 
RNA-directed DNA-methylation (RdDM) is another mechanism to influence 
chromatin alteration. It describes the process, predominantly in plants, where 
nearly all sensitive cytosine residues at the homologous regions of the 
chromatin to the trigger dsRNAs are methylated [AGRAWAL et al., 2003].  
 
3.4 The four big players  
After years of speculations and suggestions, the mechanism is now mostly 
solved. Not all of the first assumptions proved to be wrong, like the thoughts 
that the mechanism is a bit variable in different organisms, but uses the same, 
evolutionarily conserved, core components and the same pathway [PARRISH et 
al., 2000]. RNAi works as a two-step mechanism, the initiation phase and the 
effector phase. Those two steps include the cleavage of double-stranded RNA 
into small interfering RNAs by the RNase III enzyme called dicer (step one). 
These newly generated siRNAs are incorporated into a multi-protein enzyme 
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called RISC and guide the actual 
degradation of the corresponding mRNA 
(step two) [ZAMORE, 2001]. Through 
the destruction of the mRNA, no further 
translation into a protein is possible and 
further results that the displayed 
phenotype shows the function of the 
silenced gene [TIJSTERMAN et al., 
2002]. The following parts, describe the 
four key players, double-stranded RNA, 
RNase III enzyme dicer, small 
interfering RNA, and the RNA induced 
silencing complex, of the RNAi 
machinery and their function in the 
whole mechanism.  
 
3.4.1 Double-stranded RNA 
Double-stranded RNA interference is established as a very powerful, simple, 
and rapid tool to inhibit gene expression of the corresponding gene. Introduction 
of dsRNA in species as different as C. elegans, Drosophila m., and 
Trypanosoma brucei. results in cleavage of homologous endogenous 
messenger RNA [FIRE, 1999]. The transcription of the affected gene is not 
disturbed, only the accumulation of the transcripts is not possible, because of 
the degradation [CATALANOTTO et al., 2000]. 
 
“Double-stranded RNA might be as old or nearly as old as life 
on earth” [FIRE, 2007]. 
 
Fig. 3 Two-step model 
[TIJSTERMAN, et al., 2002] 
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Long time it was thought, that the key role for dsRNA was established in the 
replication cycle of viruses, and that there was no other place for double-
stranded RNA in the normal cell information. Double-stranded DNA and single-
stranded RNA was thought to be employed only as short-term information 
storage [FIRE, 2007]. Double-stranded RNAs were recognized the first time in 
plants and afterwards observed in a variety of organisms. The conservation of 
those fragments suggested an ancestral mechanism [SIJEN & KOOTER, 2000]. 
With the discovery of RNAi, it was recognized that dsRNAs can do a lot more 
than actually assumed [FIRE, 2007]. And it was found that some viruses 
developed mechanisms to partially or fully resist the degradation [FIRE, 1999]. 
Already a few molecules per cell are potent enough to trigger the silencing 
effect in C. elegans and Drosophila. So the suggestions, there might exist a 
catalytically and/or an amplification feature, were mentioned [MONTGOMERY & 
FIRE, 1998]. Without the knowledge of siRNAs, dsRNA was thought to be the 
key trigger of the silencing effect, regardless if the dsRNA origins from 
exogenous or endogenous sources [PARRISH et al., 2000]. Researchers 
figured out the effective length of dsRNA in diverse experiments. Double-
stranded RNA under 49bp was ineffective, slightly active was dsRNA with 
149bp, and obvious robust effects were displayed at a length of 505bp and 
997bp [TUSCHL et al., 1999]. Other published results indicated that dsRNA 
must be longer than ~200bp to be effective [BASS, 2000]. Further results 
pointed out that longer dsRNA are processed more efficiently than shorter ones. 
That correlated with the observations that long double-stranded RNA induces 
more effectively RNA interference [KETTING et al., 2001]. It was also figured 
out, that only exon sequences have silencing activity and no intron or promoter 
sequence is active [FIRE et al., 1998]. One exception appeared; an intron 
sequence is then effective, when also an exon sequence is present [TABARA et 
al., 1998]. Potent silencing was found only with 96% of identical sequence to 
the target, 78% and 72% resulted in no, and 88% triggered only less 
interference [PARRISH et al., 2000]. 
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3.4.2 Dicer 
Dicer, an RNase III enzyme, 
cleaves the long dsRNA into 
smaller fragments, of around 21-
25 nucleotides in length. Those 
fragments are the true 
intermediates of the RNA 
interference phenomenon and are 
referred to as small interfering 
RNAs [ZAMORE, 2001]. This 
cleavage step explains why 
dsRNA shorter than 30bp are 
inefficient to induce RNAi, in contrast to longer ones [ELBASHIR et al., 2001b]. 
RNase III is the only known enzyme that can cleave dsRNA at the specifically 
suggested site to form smaller fragments of around 21-25 nucleotides in length 
and include the characteristic structure of the 5’ end phosphate-, 3’ end 
hydroxyl-group, and two-nucleotides 3’ end overhang [BASS, 2000] [ELBASHIR 
et al., 2001b]. Dicer is an evolutionarily conserved family of proteins among a lot 
of organisms such as fungi, plants, and animals including C. elegans, 
Drosophila m., and mammals [TIJSTERMAN et al., 2002]. 
RNase III enzymes are represented by three families. The first one, the 
bacterial RNase III, is composed of a single catalytical domain and a dsRNA-
family binding domain [HANNON, 2002]. The second family is represented by 
drosha (from Drosophila), consisting of the C-termini two RNase III domains, 
one binding domain, and an N-termini with still unknown function [SHARP, 
2001] [TUSCHL, 2001]. The enzyme drosha will be further discussed in chapter 
3.4.3.2.1., biogenesis of miRNAs. The third class represents the dicer family. 
Dicer, located in the cytoplasm, is a multidomain ribonuclease III protein 
containing 6 different domains [KENT & MacMILLAN, 2004]. The N-terminal, 
composed of an ATP dependent DExH/DEAH RNA helicase domain, PAZ 
domain, and a DUF283 domain with unknown function; the C-terminal contains 
Fig. 4 Cleavage of dsRNA by dicer 
modified from [NYKÄNEN et al., 2001] 
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two RNase III catalytic domains and a dsRNA-binding motif [PADDISON & 
HANNON, 2002] [HE & HANNON, 2004]. 
Evidence for the requirement of dicer, for the RNA interference pathway, is 
existent. Homology of dicer exists among many organisms such as DCR-1 
between Drosophila and C. elegans [KETTING et al., 2001]. Some organisms 
encode more than one dicer homologue. Suggestions indicate that each dicer 
processes dsRNA from a specific source. Individuals with only one dicer 
homologue may contain proteins to help dicer recognize the different sources of 
dsRNA [MEISTER & TUSCHL, 2004]. Dicer-defective animals are sterile and 
exhibit developmental abnormalities during larval growth. Dcr-1 mutants are 
defective for RNAi in germline, but not in somatic cells [KETTING, et al., 2001]. 
For the cleavage of double-stranded RNA, ATP is needed to form the smaller 
duplex fragments [NYKÄNEN et al., 2001]. It is not clear if ATP is the limiting 
factor, because in presence of Mg2+ and absence of ATP the production of 
siRNA was also visible [AGRAWAL et al., 2003].  
Additional to the production of siRNAs, dicer is also employed in the maturation 
of microRNAs. Precursors, deriving from the nucleus, are cleaved into 
microRNAs, in a length of about 21-25 nucleotides [HE & HANNON, 2004]. It 
was also demonstrated that dicer-defective organisms displayed defective 
miRNA maturation [MELLO, 2007]. 
 
3.4.3 Small non-coding RNAs 
A new discipline developed with the discovery of the small non-coding RNAs, 
RNomics. It is the science of the structure, the enzymatic and regulatory 
function of the non-coding fragments [APPASANI, 2005]. 
Small RNA molecules are key players of an ancient and conserved form of 
silencing [ALMEIDA & ALLSHIRE, 2005]. But it is not their only function. It 
seems that they are employed in many biochemical pathways but most of the 
functions remain unknown [LAU et al., 2001]. RNA interference’s two main 
members are miRNAs and siRNAs [COUZIN, 2002]. Next to those two, tiny-
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non-coding RNAs (tncRNAs), small nuclear RNAs (snoRNAs), and small 
modulatory RNAs (smRNAs) are already discovered and certainly some more 
will be found [KIM, 2005] [TAFT et al., 2009]. 
 
3.4.3.1 Small interfering RNAs 
The function of small interfering RNAs was recognized the first time in plants 
and afterwards in Drosophila embryo lysate [COGONI & MACINO, 2000] [LIM 
et al., 2003]. It is now established that siRNAs are no byproducts of the double-
stranded cleavage reaction by dicer. Instead, they are the true intermediates of 
the RNAi reaction [ZAMORE, 2001]. Small interfering RNAs appear to be 
universal in all organisms. Only the length is a little bit variable and species-
dependent, but that might reflect the different dicer homologous [HUTVÁGNER 
& ZAMORE, 2002]. SiRNAs are double-stranded RNAs about 21-25 nucleotides 
in length. The characteristic structure of each side of each strand includes the 
5’phosphate- and the 3’hydroxyl ends and overhangs of 2 basepairs on the 3’ 
end on every side [CAPLEN et al., 2001].  
SiRNAs are incorporated into a multicomponent enzyme, termed RNA induced 
silencing complex, and function as guide RNAs to recognize the perfect 
complementary mRNA and initiate their degradation [TUSCHL, 2002]. The 
already mentioned structural characteristics are important to enter the silencing 
pathway. The phosphate group on the 5’ end is necessary for the RISC activity. 
Introduction of synthetic siRNAs with free 5’ ends are immediately 
phosphorylated [MARTINEZ et al., 2002]. In general, siRNAs with the lower 
stability at the 5’ end enter preferred RISC and are more effective silencers 
Fig. 5 Typical structure of small interfering RNA
[DYKXHOORN, et al., 2003] 
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[HANNON & ROSSI, 2004]. Small RNAs with the characteristic double-
nucleotide 3’ overhang are more effective than similar ones with blunt-ends 
[TUSCHL, 2001]. Modifications are tolerated on both ends of the sense strand 
in contrast to the antisense strand. Every chemical change at the antisense 
strand abolishes the function as guide of RNAi and no silencing effect is 
displayed [MARTINEZ et al., 2002]. After the duplex strand splits, only the 
antisense strand is detected. While the sense strand is degraded, the antisense 
strand of the RNA duplex is incorporated into RISC to cleave the mRNA starting 
from the center [AGRAWAL et al., 2003] [SHARP, 2001]. This explains why 
modifications of the sense strand cause no obvious problems [TUSCHL, 2001]. 
The target is cleaved in regular intervals, around 21-23 nucleotides, in the 
region of absolute complementarity between siRNAs and the mRNA, and get 
degraded afterwards [TIJSTERMAN et al., 2002]. Already single basepair 
mismatches between the guide strand and the target can abolish the silencing 
effect [SHARP, 2001]. 
Long double-stranded RNA injected into mammalian cells trigger non-specific 
effects. Those effects are discussed in more details in chapter 3.6., difficulties 
for RNA interference in mammals. Experiments verified that chemical 
synthesized siRNAs can bypass those effects and induce efficient mRNA 
degradation, also in mammalian cells [CAPLEN et al., 2001]. Another 
characteristic of siRNAs is, that they can function similar to miRNA and inhibit 
translation of mRNA instead of the degradation from mRNA. The mechanism 
depends on the degree of the complementarity between the siRNA and the 
mRNA [BARTEL, 2004]. 
Many advantages pushed the adaption of siRNAs as research tool. Problems, 
such as stability of the duplex and delivery into the organisms, were already 
figured out early by trying to adapt the promising antisense oligonucleotides as 
therapeutic agents. The method is easy to work with, the costs are high but 
reasonable [PAROO & COREY, 2004]. SiRNAs are highly sequence-specific, 
are working at low concentrations, and can be used for large-scale screens and 
high-throughput experiments, regarding gene function and drug validation 
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[BOESE et al., 2005]. The hope for using small interfering RNAs in the future as 
therapeutic agents is very high [CAPLEN et al., 2001]. The high efficiency, the 
specificity, and the endurance of the silencing made siRNAs one of the best 
tools for target validation in biomedical research [TUSCHL & BORKHARDT, 
2002]. Not only advantages are found for introduction of siRNAs. One limitation 
includes the transitory of the silencing mechanisms. After the transfection of 
siRNAs, the silencing effect persists only for around one week. To avoid this 
drawback, diverse delivery methods were developed, such as siRNA 
expressing vectors [PADDISON et al., 2002]. 
 
3.4.3.1.1 Newly discovered small RNAs  
In the last years, many different subclasses of small interfering RNAs were 
discovered. Here, I provide a short overview of those I came across during my 
research.  
Repeat-associated small interfering RNAs (rasiRNAs) are composed of 
homologous regions of repetitive DNA such as transposons, retrotransposons, 
centromeric repeats, satellite, and microsatellite DNA [DYKXHOORN & 
LIEBERMAN, 2005]. Their role is established in heterochromatin silencing by 
regulation of methyltransferases and histone-modifying enzymes [KIM, 2005]. 
Endogenous small interfering RNAs (endo-siRNAs), 22nt, are generated from 
protein-coding sequences and are suggested to have perfect complementarity 
to their targets in Caenorhabditis elegans [AMBROS et al., 2003]. The 
biogenesis is so far not clear, but it might be possible that they involve dicer, 
RNA-dependent RNA polymerases, and other mechanisms shared with the 
RNAi pathway [FISCHER, 2010]. It seems that their role is established in 
chromatin methylation and silencing [LAI, 2003]. 
Small scan RNAs (scnRNAs) are also involved in the regulation of histone 
methylation. It is suggested that they are also generated by dicer, but their 
whole biogenesis and their roles are still unknown and need further research 
[KIM, 2005].  
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The endogenous trans-acting RNAs (tasiRNAs) are, so far, discovered only in 
plants and nematodes which exhibit RNA-dependent RNA polymerases activity. 
It seems that they origin from introns of non-coding genes. Their functions 
remain to be identified [KIM, 2005]. 
New studies emerged that some siRNA might be able to trigger an interferon I 
response, the production of pro-inflammatory cytokines, and the activation of 
nuclear factor-кB. All those siRNAs are referred to immunostimulatory RNAs 
(isRNAs). It seems that small RNAs with 3’ blunt-ends and GU-rich sequences 
have greater potential to induce those responses than others [SHAN, 2010]. 
Also other important characteristics like length, double/single-strand 
configuration, and nucleoside modifications have influence on the 
immunostimulatory power [SCHLEE et al., 2006]. 
 
3.4.3.2 MicroRNAs 
The discovery of miRNAs was very surprising, nobody expected small RNAs to 
encode, instead of a protein, an RNA fragment [MELLO, 2007]. The first 
identified microRNA, in 1993, was lin-4 and 7 years later the second one, let-7, 
was found [HE & HANNON, 2004]. Those two were referred to as small-
temporal RNAs (stRNAs), because of their function in regulation of the 
developmental timing in C. elegans [LAU et al., 2001]. Lin-4 seemed to be 
restricted to C. elegans and did not have any homologous in other organisms. 
So in the beginning, it was thought that the phenomenon is limited to C. 
elegans. After the detection of let-7 and its homology in other organisms the 
picture changed, and researchers recognized that they discovered only the tip 
of the iceberg [ZAMORE, 2001]. Till 2002, hundreds of miRNAs have been 
identified in organisms, ranging from worms to flies to humans and plants 
[AGRAWAL et al., 2003]. The approximated numbers of miRNAs in those 
organisms range between 0.5% and 1% of all contained genes in the genome, 
for example in C. elegans: 105 ± 15 and in humans: 230 ± 30. In single-cell 
organisms no miRNAs were identified [LIM et al., 2003]. This whole group of 
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non-coding tiny RNAs is referred to as microRNAs, including the subclass of 
stRNAs [LAU et al., 2001]. Some of them are highly evolutionarily conserved 
between flies, worms, and humans [MOSS, 2002]. Nearly one third of all known 
C. elegans miRNAs are close in sequences to one or more insects, and/or 
vertebrate miRNAs [AMBROS et al., 2003]. Others, like lin-4 exist only in one 
organism [MOSS, 2002]. 
Functions of miRNAs are largely unknown, except for lin-4 and let-7 [AMBROS, 
2001]. The fast rising number of identified miRNAs established the idea that not 
all of the identified miRNAs work as regulation factor of developmental timing 
[HE & HANNON, 2004]. This argument and the evolutionarily conservation 
implied, that they must function in a variety of regulatory pathways, additionally 
to their already discovered role as regulation factor in form of lin-4 and let-7 
[LAU et al., 2001]. Suggestions are even that far; if miRNAs are as widespread 
and diverse as they seem to be, they might be able to play their part as 
regulation/control factors in multifaceted pathways [LEE & AMBROS, 2001]. It 
would be possible that miRNAs could regulate any imaginable biological 
process involving RNA/RNA or RNA/protein interactions [AMBROS, 2001]. And 
the evidence is mounting, that animal miRNAs are more numerous and that 
their regulation functions are more present than was suspected in the first place 
[AMBROS, 2004]. Actually it might be that miRNAs, rather than siRNAs, are the 
true intermediates of the small-mediated regulation of gene expression 
[GROSSHANS & SLACK, 2002]. 
The first miRNA showing a function other than control of developmental timing 
was found in Drosophila m., called bantam. Bantam is involved in the regulation 
of apoptosis and cell proliferation in the developing fly [AMBROS et al., 2003]. A 
lot of research was done and miRNAs are now successfully associated with 
tissue specifications, cell death, fat metabolism, and cell proliferation in flies, 
neuronal patterning in nematodes, modulation in hematopoietic lineage 
differentiation in mammals, and control of leaf and flower development in plants 
[LAGOS-QUINTANA et al., 2001] [BARTEL, 2004]. Evidence was found that 
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deregulations of miRNAs are associated with human diseases such as cancer 
[DYKXHOORN & LIEBERMAN, 2005]. 
MicroRNAs are produced from ~70 nucleotide endogenous hairpin stem-loop 
precursor and are further processed by dicer to their single-stranded mature 
form of ~22 nucleotides [DYKXHOORN, et al., 2003]. MiRNAs recognize their 
targets by imperfect base-pairing (50-85%) to the 3’ UTR (untranslated region) 
region of the target mRNA, causing repression of the translation and inhibition 
of the protein synthesis [WADHWA et al., 2004]. As noted above, dicer does 
also generate microRNAs. So it is not a surprise that they appear to have the 
same length as siRNAs, are just a little tighter in their distribution, and 20-24 
nucleotides in length. Also the characteristic structures of dicer cleavage 
products, the 5’phosphate group and two-nucleotide 3’ overhangs were not 
missing [LIM et al., 2003]. 
It is important to mention that there is one main difference between miRNAs in 
plants and animals. In plants, miRNAs function as natural endogenous siRNAs. 
Not like in animals, where miRNAs partially bind to the 3’ UTR of the target and 
inhibit the mRNA translation, miRNAs in plants work like siRNAs and trigger 
degradation of their targets. This results from the fact that plant miRNAs are 
mostly perfectly complementary to their target [NOVINA & SHARP, 2004]. 
Only little is known about the exact mechanism of miRNAs, and this leaves a 
broad range for speculations and suggestions [HE & HANNON, 2004]. It is still 
unclear if every miRNA has one, few, or many targets, or if one target might be 
regulated by multiple miRNAs [MOSS, 2002]. It was assumed, that miRNAs 
targeting a single sequence, had the opportunity to undergo evolutionary 
determined modifications more easily compared to conserved miRNAs, which 
may act on more than one target sequence [LAGOS-QUINTANA et al., 2001]. 
In fact, it was discovered that single miRNA species can bind to different mRNA 
targets, and multiple binding sites implicated the possibility that more than one 
miRNA attacks the same target sequence to achieve translational inhibition 
[DYKXHOORN & LIEBERMAN, 2005]. 
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Still one of the major hurdles is the prediction of miRNA targets in animals. It is 
more difficult because of their imperfect base-pairing. It is necessary at this 
point, to mention, that RNA cleavage by miRNA could be overrepresented, for 
the reason, that their targets can be identified easier. MiRNA databases, 
containing all up to date information of newly published miRNAs, are 
established. But there is still a lot of research to do, to clarify all the unanswered 
questions [HE & HANNON, 2004]. Nowadays, synthetic miRNAs can be 
produced to mimic siRNAs or miRNAs and target special genes for silencing 
[McMANUS et al., 2002].  
 
3.4.3.2.1 Biogenesis of miRNAs  
It is confirmed that miRNAs origin rather from intronic regions and from 
sequences between protein-coding genes than, like predicted, from genes itself 
[MOSS, 2002]. Many seem to be regulated by their own promoters, but some 
use the promoter from the introns, which would be a very smart mechanism to 
express miRNA and a protein at the same time. Some miRNAs occur in 
clustered regions in the genome, which are sometimes, but not always, related 
to each other [BARTEL, 2004]. Many miRNAs are continually expressed, and 
others appear only at specific developmental stages or in certain tissues 
[AMBROS, 2001]. The amount from a few hundreds to 50,000 molecules per 
cell is not very predictable [BARTEL, 2004]. 
The generation of miRNAs requires two different steps in two different parts of 
the cell. MiRNAs were transcribed by Pol II in the nucleus as long transcripts 
called pri-miRNAs (primary microRNAs). The first cleavage step to generate the 
mature miRNA starts afterwards, also in the nucleus [LEE et al., 2002]. Drosha, 
an RNase III enzyme, containing proline-rich regions and an arginine-serine-rich 
domain, two RNase III domains, dsRNA binding domain, and an amino-terminal 
with unknown function, cleaves pri-miRNA into pre-miRNA hairpins 
[MURCHISON & HANNON, 2004] [HE & HANNON, 2004]. Pre-miRNAs, also 
known as miRNA precursors, are about 60 to 70 nucleotides in length including 
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a stem loop structure and bulges. Drosha leaves a staggered cut and a typically 
phosphate group on the 5’ terminal. This cut already characterizes one end of 
the mature miRNA. The precursor is actively transported into the cytoplasm by 
Ran-GTP and exportin-5, an export receptor. The second end is cleaved and 
defined in the cytoplasm by RNase III enzyme dicer. After the cleavage of both 
strands of the hairpin precursor a 5’phosphate group and two-nucleotides 3’ 
overhang are left. Dicer may have a preference for the 5’phosphate and the 
dinucleotide overhang of the stem loop [BARTEL, 2004]. Dicer is important in 
the maturation of miRNAs. In fact, in dicer-deficient mutants, accumulation of 
pre-miRNA hairpins was shown, while mature miRNAs disappeared [LEE et al., 
2002]. The mature miRNA duplex is a fragment, similar in size like siRNA, only 
without perfect complementary and single-stranded, because it derives from 
one part of one arm of the former precursor loop. The double-stranded 
miRNA:miRNA* composed by the mature miRNA and the complementary 
strand miRNA*, does not survive very long in contrast to single-stranded 
miRNA. The mature miRNA associates with a multiprotein complex called 
miRNA ribonucleoprotein complex (miRNP), which might be a particular 
subtype of RISC. The single-stranded miRNA gets incorporated into miRNP 
while miRNA* gets degraded. Which strand gets loaded into RISC/miRNP 
depends on the 5’ end. The one which is not that tightly bound, gets 
incorporated. Very rarely, both get loaded into miRNP; this happens when the 
duplexes have nearly the same stability at their 5’ ends [BARTEL, 2004]. After 
incorporation, the miRNA guides the base-pair to the 3’ UTR region of the target 
to inhibit the expression. It is still unclear, at which exact point of the protein 
synthesis the translation occurs [FISCHER, 2010].  
Also in the biogenesis, plants differ from animals. Actually, in plants, 
researchers have not found any pre-miRNAs. This fact indicates that both 
cleavage steps happen in the nucleus by drosha [BARTEL, 2004]. 
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Fig. 6 A model for miRNA biogenesis and the translational inhibition of the target RNA 
modified from [HE & HANNON, 2004] 
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3.4.3.2.2 Small temporal RNAs: lin-4 and let-7  
Lin-4 and let-7 are both members of the small 
temporal RNAs (stRNAs), which present a subclass 
of miRNAs, but only the second mentioned one is 
evolutionarily conserved. Their function lies in 
controlling the developmental timing in 
Caenorhabditis elegans [LEE & AMBROS, 2001]. Lin-
4 homologous were only found in C. elegans and 
related species of C. elegans. That was the reason, 
that, till the identification of the second stRNA, let-7, it 
was believed to be a nematode-wide unique feature. 
In contrast to lin-4, let-7 is conserved among various 
organisms including mollusks, flies, zebrafish, mice, 
and human [GROSSHANS & SLACK, 2002]. 
As quoted above, lin-4 and let-7 are miRNAs. That 
means that those two also display all the 
characteristic marks of miRNAs, such as, that they do 
not encode for a protein, are transcribed as pri-
miRNA, are further processed to hairpin precursor 
containing the typical bulges and stem-loops, maturate through dicer, and the 
down-regulation of the target occurs without affecting the mRNA level by 
degradation. Because of the surprising fact, that lin-4 encodes small RNAs 
instead of proteins, lin-4 could remain so long undetected [MELLO, 2007]. It is 
established that lin-4 encodes 22 nucleotide long, non-coding RNA fragments. 
Lin-4 RNA is antisense complementary to multiple conserved 3’ UTRs of lin-14 
and lin-28. Experiments discovered that lin-4 affects negatively the translation of 
both, by basepairing to their 3’ UTRs. The down-regulation of lin-14 results in 
developmental change from the first larval stage (L1) to the second stage (L2) 
in the nematode C. elegans. Further, the down-regulation of lin-28 in the second 
larval stage results in developmental progress into the third one (L3) [HE & 
HANNON, 2004]. 
Fig. 7 Predicted structure of
lin-4 and let-7 
[BARTEL, 2004] 
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Let-7 is phylogenetically conserved, encodes a 21 nucleotide long RNA, and 
appears to operate in the same way as lin-4. Let-7 acts by binding to the 3’ UTR 
of lin-41 and hbl-1. This results in their translational repression and further in the 
transformation of the nematode from the fourth larval stage (L4) into an adult 
worm [HE & HANNON, 2004]. 
 
3.4.3.3 Difference between siRNAs and miRNAs 
MicroRNAs and small interfering RNAs share some evolutionary conserved 
pathways, but differ in some others; they can replace each other under special 
conditions, but are not identical [BARTEL, 2004]. 
MicroRNAs and small interfering RNAs are identical in their length (21-25 
nucleotides) and display the typical 3’hydroxyl-, 5’phosphate end and the 
dinucleotide overhang on 3’ termini. Both require dicer for their maturation and a 
multiprotein complex (RISC / miRNP) to fulfill their destiny. MiRNAs are usually 
evolutionarily conserved endogenous encoded sequences, and form precursor 
hairpin transcripts with imperfect complementarity. Each hairpin molecule 
generates one single-stranded miRNA processed from one arm [LIM et al., 
2003]. Typically, miRNA regulates negatively the target expression by binding 
imperfectly to 3’ UTR regions at multiple sites of the mRNAs without cleavage 
and degradation [LAU et al., 2001]. In contrast to miRNAs, siRNAs often 
originate from double-stranded RNA molecules such as transposons and 
viruses, or are rarely conserved endogenous siRNAs. Every double-stranded 
RNA produces numerous double-stranded siRNAs, which are perfectly 
complementary to their target sequence [LIM et al., 2003]. Noted already in one 
of the previous chapters, small interfering RNAs basepair with perfect 
complementarity to their target mRNA and initiate the degradation. MiRNAs and 
siRNAs are interchangeable. It depends on the complementarity, if the complex 
guides the degradation or the translational inhibition of the target mRNA. If 
miRNA and the target are sufficiently complementary, the target is cleaved at 
the same site as seen for siRNA-guided degradation. Otherwise, without 
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enough complementarity, the miRNA directs a translational repression 
[BARTEL, 2004]. 
 
3.4.3.4 Small nuclear RNA  
This highly evolutionarily conserved group of small RNAs is classified into two 
different classes, first C/D snoRNAs and second, H/ACA-box snoRNAs. The 
first mentioned ones are between 70 and 120 nucleotides long and are 
implicated to guide the methylation step of the target RNAs. H/ACA box 
snoRNAs are longer, between 100 and 200 nucleotides in length, and are 
employed to guide pseuduridulation. It seems that small nuclear RNAs are a 
complex, made from two miRNA-like hairpins and further, snoRNAs themself 
produce another small RNA class called sdRNA (sno-derived RNAs). 
Experiments displayed that the biogenesis of sdRNA is controlled by 
components of the RNAi pathway and further, that sdRNAs are implicated in the 
regulation of gene expression and transcriptional silencing [TAFT et al., 2009]. 
Fig. 8 aǀ siRNA pathway bǀ microRNA pathway
[DYKXHOORN et al., 2003] 
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3.4.3.5 Tiny non-coding RNAs  
Tiny non-coding and endogenous siRNAs are similar in their biogenesis; the 
difference is that tncRNAs are transcribed from non-coding genomic sequences 
[LEE et al., 2006]. They occur to have the similar length like miRNAs, are alike 
miRNAs in view of imperfect complementarity to their target, but lack in the 
characteristic hairpin precursor sequences. For this reason they are not counted 
as members of miRNAs. TncRNAs, in contrast to miRNAs, are rarely conserved 
among related species [AMBROS et al., 2003]. The functions are still unknown, 
but the discovery, that tncRNAs and siRNAs share some components of the 
RNAi pathways like DCR-1 and RDE-4, suggests, they might be involved in the 
gene silencing mechanism [LEE et al., 2006]. 
 
3.4.3.6 Small modulatory RNAs 
Small modulatory RNAs are 20 nucleotides long and were identified in neural 
stem cells of mice [NOVINA & SHARP, 2004]. They appear to have a role in 
neural differentiation. The biogenesis and the pathway of their function remain 
to be worked out [KIM, 2005]. 
 
3.4.3.7 PIWI-interacting RNAs 
PIWI-interacting RNAs are referred to as piRNAs because of their interaction 
with a subclass of the argonaute protein family, the PIWI-proteins [PETERS & 
MEISTER, 2007]. PiRNAs are around 24-30 nucleotides long and are 
generated dicer- and drosha-independently. So far only one function could be 
investigated. PIWI-interacting RNAs are implicated in the transposon silencing 
of flies to maintain the genome stability [HUTVÀGNER & SIMARD, 2008]. 
Another subclass of small RNAs was detected in C. elegans, called 21U-RNAs. 
Those small RNAs contain a uridine 5’- monophosphate and a modified 3’ end. 
Later it was figured out, that those 21U-RNAs count actually as piRNAs, in the 
case of C. elegans. In other organisms those two are different subclasses of 
small RNAs [FISCHER, 2010].  
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3.4.4 RNA induced silencing complex and microRNA ribonucleoprotein 
complex 
RNA induced silencing complex and microRNA ribonucleoprotein complex are 
the effector enzymes of the RNA Interference phenomenon. Both are 
multiprotein complexes with the difference that RISC incorporates siRNA and 
miRNA enters miRNP. The complexes vary in size and composition, and have 
several forms, which indicate already their different functions. Both have the 
ability to cleave the target mRNA through one of the argonaute proteins, which 
works as nuclease [MEISTER & TUSCHL, 2004].  
Some parts of the RISC complex have been identified, but still, some parts 
remain to be discovered. The first piece, described in Drosophila, was 
argonaute 2 (AGO2) [BERNSTEIN et al., 2001]. AGO2 is a member of the big 
argonaute family. It is highly conserved and a small (~130 kDA), basic protein, 
homologous to RDE1 in C. elegans, QDE-2 in Neurospora c., and AGO1 in 
Arabidopsis t., containing a PAZ and PIWI domain (called PPD domains) 
[AGRAWAL et al., 2003]. All argonaute proteins possess the two characteristic 
domains, a piwi-argonaute-zwille (PAZ) and a PIWI domain. Only recently a 
third functional domain was found, the MID-domain. It seems that the MID-
domain, after the recognition of the 5’phosphate of small RNAs, binds them 
tightly to the argonaute protein [PETERS & MEISTER, 2007]. Early studies 
proved the suggestions, that PAZ might interact as domain between dicer and 
AGO. PAZ identifies the terminal of the basepaired duplex and the 
characteristic two-nucleotide 3’ overhangs [MEISTER & TUSCHL, 2004]. 
Recent experiments implicated argonaute proteins in diverse functions like 
embryonic development, cell differentiation, regulation of protein synthesis, 
maintaining of the genome stability, in translational repression, and are involved 
as co-factor in the methylation for heterochromatic silencing [PETERS & 
MEISTER, 2007] [HUTVÀGNER & SIMARD, 2008]. Argonaute proteins might 
also play their part in the development of some certain diseases like cancer or 
autoimmune diseases [PETERS & MEISTER, 2007]. Some organisms, which 
have lost their entire family of argonaute genes, are not able to respond with an 
RNAi effect at all [HUTVÀGNER & SIMARD, 2008]. Next to AGO2, additional 
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proteins and factors are identified for RISC: two RNA-binding proteins, vasa 
intronic gene (VIG) and dFMR (homologous to the human fragile X mental 
retardation protein), and a minimum of one protein with nuclease function 
(Tudor-SN) activity [AGRAWAL et al., 2003] [KENT & MacMILLAN, 2004]. 
Recently the long-expected slicer activity, responsible for cleaving the mRNA, 
was discovered as an attribute of the human AGO2 [KIM, 2005]. In the human 
model two proteins from the argonaute family eIF2C1 and eIF2C2, as well as 
Gemin3 and Gemin4 were identified as parts of the complex [CERUTTI, 2003]. 
The phosphate group on the 5’ end of siRNA is required to access RISC. 
Introduction of synthetic siRNAs without phosphorylated 5’ ends were 
immediately phosphorylated by an endogenous kinase [MARTINEZ et al., 
2002]. Also other critics are implicated in the incorporation like relative and 
absolute stability. Functional asymmetry means, that the strand with the lower 
thermodynamics (is less tightly bound to its complementary) enters the RISC 
and the other strand gets degraded [SCHWARZ et al., 2003]. In general, 5’ 
terminus, starting with an A-U basepair, is preferred. Also energy differences 
can favor one strand [SCHEPERS, 2005]. Naturally, the antisense strand is the 
one which gets incorporated into RISC. This knowledge is very handy for the 
design of synthetic siRNA. It got predictable which strand will enter the RISC 
complex and guides the degradation [SCHWARZ et al., 2003]. The degree of 
the degradation depends on the stability of the target RNA. It is shown, that 
stable RNAs are to a greater extent degraded than RNAs which are quickly 
synthesized and degraded in the organism [FIRE, 1999].  
RISC is generated as precursor molecule and gets activated by ATP to form 
RISC* [HANNON, 2002]. The early suggestions proved to be right, which 
placed an RNA helicase of the DEAH-box helicase super family as the 
mechanism to unwind the duplex siRNA [SHARP, 2001]. If the ATP requirement 
is necessary to change the RISCs conformation / composition or if the ATP-
requirement is needed for the destabilization of the double-stranded RNA was 
long not known [MEISTER & TUSCHL, 2004]. Later it was figured out that the 
cleavage step itself does not necessarily require ATP, but in presence  
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of ATP the reaction is 
more efficient, and Mg²+ is 
required [MONOHARAN, 
2004]. While the antisense 
strand enters RISC to 
guide the complex to the 
target RNA and induce the 
degradation step, the 
sense strand is left behind 
for degradation by 
exonuclease activity 
[DYKXHOORN et al., 
2003] [WADHWA et al., 
2004]. It depends on the 
rate of complementarity if 
the silencing is achieved through mRNA degradation or through translational 
repression [LEUNG & WHITTAKER, 2005]. It was detected that cleavage of the 
target mRNA appeared only in regions of complementarity with the introduced 
dsRNA/siRNA after 21-23 nucleotide intervals. The cleavage site, relative to the 
5’ end of the guide-strand, is located next to the center of the homologous 
target, between nucleotide 11 and 12, downstream [ELBASHIR et al., 2001b]. 
Incorporated siRNA into RISC or miRNA into miRNP, those enzymes can direct 
multiple rounds of target cleavage and give an explanation for the high 
efficiency of RNAi. The stability might be the limitation of the reaction. Eri-1 is 
suggested to hide the siRNAs from the RISC complex by cleaving off their 3’ 
overhang [MURCHISON & HANNON, 2004]. Some ideas place RdRPs after the 
cleavage, to convert parts of the mRNA to duplex forms. These newly 
generated duplexes might reenter the RNAi cycle from the beginning cleavage 
step through dicer [AGRAWAL et al., 2003]. 
To explain the differences of the RNAi pathway regarding the heterogeneity of 
RISC, it is important to mention, that many organisms have more than one AGO 
protein; for example C. elegans possess 20, humans 8. And not to forget that 
Fig. 9 Target recognition and target cleavage by the RISC
complex 
modified from [NYKÄNEN et al., 2001] 
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the most organisms also have more than one different dicer protein [MEISTER 
& TUSCHL, 2004]. 
 
3.5 Regulation of RNAi 
Till now, only little is known about the regulation of the RNA interference 
pathway. Recently, a small molecule, enoxacin, was identified. It is a non-toxic 
molecule which was not seen to trigger non-specific effects, and further seems 
that its enhancing characteristics work universal. Results indicate that enoxacin 
improves the efficiency of the knockdown effect in vivo, by reduction of the 
required dosage. The effect was not only displayed on siRNA-mediated RNAi, 
also miRNAs seem to be effected. According to the experiment, levels of pri-
miRNAs and pre-miRNAs decrease while the level of the mature miRNAs 
increase [SHAN et al., 2008]. The, in the previous chapter mentioned, gene eri-
1 might also play its part in the regulation of RNAi. It seems to stop the usage of 
siRNAs for multiple rounds by cleaving off the two-nucleotide 3’ overhang. After 
this cleavage step, siRNAs appear to be invisible for the RISC and cannot get 
incorporated anymore [MURCHISON & HANNON, 2004]. Another part of the 
negative regulation of RNAi might be the gene lin-35, which was found only 
recently in C. elegans [FISCHER, 2010]. 
 
3.6 Difficulties for RNA interference in mammals 
RNA interference, triggered by introduction of long dsRNA (~500bp), brought a 
lot of information about gene functions in various organisms. It started with C. 
elegans, further in Drosophila melanogaster. It seemed that it worked perfect in 
all invertebrates, but in mammals the mechanism failed [LEUNG & 
WHITTAKER, 2005]. These first problems, mammalian organisms were not 
amenable for RNAi, indicated different, not identical pathways between 
mammals and lower organisms [MILHAVET et al., 2003]. The major problem 
was the activation of one arm of the innate immune pathway, including a non-
specific interferon response, which is triggered by introduction of long double-
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stranded RNA in mammalian somatic cells [HANNON, 2002] [HANNON & 
ROSSI, 2004].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interferons, signaling molecules, are secreted naturally in cells, after the cells 
get infected by RNA-viruses or other overrepresented dsRNA [TUSCHL, 2001]. 
The dsRNA-dependent protein kinase gets activated by -interferon 
Fig. 10 Activation of the PKR response and the 2‘-5‘ oligoadenylate synthase pathway 
[DYKXHOORN & LIEBERMAN, 2005] 
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[SCHEPERS, 2005]. As consequence, PKR inactivates the translation factor 
eIF2α by phosphorylation. This pathway results in a general shutdown of protein 
synthesis, and in an apoptotic and non-apoptotic cell death. A second pathway 
gets activated too [CAPLEN et al., 2001]. Double-stranded RNAs, longer than 
30 nucleotides, induces, next to the activation of the PKR pathway, the 
production of 2’-5’ oligoadenylate synthase. Which further results in the 
activation of a sequence-nonspecific RNase (RNase L) [DYKXHOORN et al., 
2003]. RNase L cleaves single-stranded RNA in a non-specifically way, that 
leads to a general degradation of the mRNA and to general shutdown of the 
protein synthesis of the infected cell [WADHWA et al., 2004]. 
The stimulation of the interferon response by dsRNA is length-dependent. 
Double-stranded RNAs longer than 11 basepairs can already interact with PKR, 
but double-stranded RNAs less than 30 nucleotides cannot trigger the full PKR 
response [SCHLEE et al., 2006]. For the full PKR activation, at least dsRNAs 
longer than 80 nucleotides are required [CAPLEN et al., 2001]. In 2001, Tuschl 
and co-workers found in Drosophila embryo lysates, that chemical synthesized 
siRNAs can bypass this reaction. This method was further processed, so that 
an interference response in cultured mammalian cells was successfully 
displayed [ELBASHIR et al, 2001a]. Those synthesized small interfering RNAs 
mimic the natural dicer product, including all the siRNA characteristic structures, 
5’phosphate and 3’hydroxyl group, and the two-nucleotide 3’ overhangs. With a 
length of 21 nucleotides they are too short to trigger the non-specific response, 
but are long enough to activate the full RNAi mechanism [HANNON, 2002]. This 
newly discovered possibility leads to a widespread use to study gene functions 
in general and in particular genes, which are known to be involved in inheritable 
diseases [DYKXHOORN et al., 2003].  
There are still drawbacks to deal with. First is to mention, the transient 
characteristics of the silencing effect. The ability of amplification and spreading, 
like in plants and C. elegans, is not emerged in mammals, because mammals 
lack the RdRP enzymes [HANNON, 2002]. This means that the RNAi effect is 
restricted to four to eight cell divides and abolishes afterwards, because of the 
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dilution of the siRNAs through cell division. Afterwards, the cells recover and 
cannot display any RNAi effect anymore [WADHWA et al., 2004]. It is possible 
to achieve a silencing effect up to weeks, in terminally differentiated and non-
dividing cells such as neurons [DYKXHOORN & LIEBERMAN, 2005]. Second, it 
is important to keep in mind, that chemically synthesized siRNAs are not able to 
perform a complete “knock-out” of the target. Instead it is always a “knock-
down” technique [SHI, 2003]. Third, a big challenge is still the transfection of the 
synthesized siRNAs. Further information about synthetic siRNAs is given in 
chapter 3.8.1., RNA interference through chemically synthesized siRNAs. 
Fourth, and possibly the biggest problem is, as recent experiments displayed, 
that also synthetic generated siRNAs as well as DNA vectors expressing 
shRNAs are not short enough to bypass the immunorecognition. Both are able 
to induce the expression of parts of the interferon pathway in some cell types 
[HANNON & ROSSI, 2004]. It was shown that the levels of, for example, type I 
interferon, interleukin 8, tumor necrosis factor-alpha, were increased. So, the 
results have to be interpreted very carefully [AULNER & JAGLA, 2008]. 
 
3.7 Structural design and chemical modifications 
RNAi is a phenomenon based on the homology between the trigger and the 
target. For that reason, the sequence of the trigger must be selected carefully to 
avoid cross-interferences and off-target effects. The critical cut-off point for 
cross interference is about 80% of similarity [BOSHER & LABOUESSE, 2000]. 
 
3.7.1 Structural information for the design of double-stranded RNAs 
It was already mentioned that neither the sense, nor the antisense strand alone 
had silencing effects, and a duplex structure is required [ZAMORE et al., 2000]. 
Important is, that the dsRNA includes a region of at least 88% of 
complementarity between the target and the trigger to induce the silencing 
effect [TIJSTERMAN et al., 2002]. The length is one of the key factors. Double-
stranded RNAs smaller than 49bp are ineffective, slightly active about 149bp, 
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and efficient with a length of 505bp and 997bp [TUSCHL et al., 1999]. Usually, 
dsRNA greater than 500bp are used [BOSHER & LABOUESSE, 2000]. Longer 
dsRNAs are more efficiently cleaved by dicer. This results in a larger amount of 
siRNAs, then shorter dsRNAs. Another fact to consider are modifications, either 
at the backbone or on the bases of the RNA. In general, modifications of the 
antisense strand of the duplex decrease the speed of RNAi more efficient than 
modifications of the sense strand [ZAMORE, 2001]. Also, promoter sequences 
and intronic sequences should be avoided, because they cannot trigger an 
effective silencing response [HANNON, 2002]. 
 
3.7.2 Parameters for the design of small interfering RNAs 
It is important to say, that the two main critics for the design of siRNAs are, that 
the functionality and the specificity gets maximized [BOESE et al., 2005]. There 
are some key reasons, why the design of siRNAs and transporter molecules, 
emerged as such an important field of research. First, the improvement of the 
stability and the thermodynamic characteristics of the siRNAs are important for 
therapeutic applications. Small interfering RNA duplexes are quite stable and do 
not need chemical modifications to extend the half-life in cell-cultures. For 
applications in vivo, the picture changed. It is necessary to increase the half-life 
of siRNA duplexes and their thermal stability to escape the degradation of 
nuclease digestion [PAROO & COREY, 2004]. For example, through backbone 
modifications of the siRNA, they were able to stand against the serum 
nucleases and the half-life of the siRNAs got increased [HANNON & ROSSI, 
2004].  
Second, the biodistribution and the pharmacokinetic qualities have to be 
enhanced. After injection, siRNAs are detectable up to 72 hours and primarily 
accumulation appears in the liver and the kidneys [PAROO & COREY, 2004]. 
During cell-divisions, the originally injected siRNAs get diluted and the RNAi 
effect abolishes quickly [LEUNG & WHITTAKER, 2005]. But through chemically 
modification it was possible to induce the silencing effect from around 5 days up 
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to several weeks [DYKXHOORN & LIEBERMAN, 2005]. The route of delivery 
has to be optimized and the potential to use siRNAs as therapeutic agents has 
to be maximized [PAROO & COREY, 2004]. 
Third, the affinity to the target must be increased with the help of chemical 
modifications to avoid off-target effects [PAROO & COREY, 2004].  
Fourth, in the future, for the introduction of siRNA as a novel and functional 
therapeutic molecule, chemical modifications will be required. Ideally, 
modifications improve the resistance against cellular destruction and increase 
the cellular uptake [HADWIGER & VORNLOCHER, 2005]. 
Some limitations should be considered. For example, cells like neurons and 
muscle cells are more difficult to transfect in contrast to stem cells, fibroblasts, 
and tumor cells [MILHAVET et al., 2003]. Another disadvantage, it is a time 
consuming process and the costs are astronomically [BOESE et al., 2005]. One 
of the main challenges is to provide an enhanced ability of the silencing effect 
regarding higher efficiency, specificity, and potency at which less chemical 
modifications stands for less cell toxicity [PAROO & COREY, 2004] [JACKSON 
& LINSLEY, 2004]. And a reduce amount of siRNA stands for a decrease 
chance for off-target effects [HANNON & ROSSI, 2004]. Also the transportation 
into the target tissue is still a huge challenge as well [PAROO & COREY, 2004]. 
But in the best case scenario, the ideal siRNA is absolutely specific and down-
regulates only the target gene of interest without any side effects, works in low 
dose, and is very effective [JACKSON & LINSLEY, 2004]. 
The natural characteristics and required structure for siRNAs includes the two-
nucleotide 3’ end overhangs on both sides, the hydroxyl group on the 3’ end, 
and the phosphorylated 5’ end. In fact, RNA duplexes with two-nucleotides 
overhang are more efficient in mRNA degradation than the similar ones with 
blunt-ends, or with a four nucleotide overhang [ELBASHIR et al., 2001b]. In 
general, the 5’phosphorylated antisense RNA, about 22 to 40 nucleotides in 
length, activates the gene silencing phenomenon. For that reason, modifications 
on the 5’ end of the antisense strand are not tolerated at all, several mutations 
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of the antisense strand resulted in a non-RNAi response, in contrast to 
modifications on both sides of the sense strand and the 3’ end of the antisense 
siRNA [MARTINEZ et al., 2002]. 
So, it is already obvious, that for a siRNA approach some important facts have 
to be considered, including the selected siRNA sequence of the target gene, 
usage of either chemically synthesized siRNAs or construction of plasmids 
transporting DNA sequences, optimized transfection methods for the used 
approach, cell culture conditions, type and amount of transfection agent, quality 
and amount of siRNA, length of the exposition time of siRNA on to the cells, and 
monitoring/controlling of the silencing efficiency with both, a positive and a 
negative control [AGRAWAL et al., 2003] [MILHAVET et al., 2003]. Parameters, 
especially for the design of the siRNA, are the length, the secondary structure, 
the sugar backbone, and the sequence specificity. Some basic rules emerged, 
like, in general the G/C concentration should be kept between 30 and 70%, the 
sequence of one strand should be AA(N19)TT, the 2nucleotide 3’ overhang of 
uridine should not be missing, the length of the siRNA should be 21 nucleotides, 
and the two characteristic groups, the 5’phospate, and the 3’hydroxyl, must be 
present [AGRAWAL et al., 2003]. A lower thermodynamic stability between the 
last bases counted from the 5’ end, of the antisense strand, as well as a lower 
thermostability in the middle of the siRNA (9-14 basepairs) are recommended, 
because this enhances the incorporation into RISC [DYKXHOORN & 
LIEBERMAN, 2005]. A/U basepairs have less binding energy, compared to G/C 
bindings, which leads to the recommendation of the two uridine overhang at the 
5’ end. For some positions, favorable basepairs emerged, like for position 1: 
C/G, 3: G/C, 10: A/U, 19: A/U, at position 11: A, G, or C increase the chance for 
a functional effective siRNA. Mismatches should not occur, but in general, 
mismatches at the end of the siRNA have more influence on the RNAi activity 
than mismatches located in the center [JAGLA & AULNER, 2008]. The 
importance of the sequence position can be seen in the ratio of sense/antisense 
strands, and which of those two actually enters the RISC complex [MEISTER & 
TUSCHL, 2004]. 
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One important point is to identify the mechanisms of immunorecognition of RNA 
regarding to avoid the design of immunostimulatory RNAs; or for the future, to 
design potent, useful immunostimulatory RNAs with both functions included, 
silencing and immunostimulation. The novel drug might be effective for disease 
such as viral infections and cancer [SCHLEE et al., 2006]. Characteristics for 
isRNAs are 3’ blunt-ends and rich sequences of GU [SHAN, 2010]. And it is 
never a mistake to check, if there are already tested siRNA for the intended 
target gene [JAGLA & AULNER, 2008]. 
 
Fig. 11 The design of an effective siRNA
[LEUNG & WHITTAKER, 2005] 
47 
  
3.8 Special delivery methods 
Two different possibilities exist to induce the intended silencing effect, either 
through synthetic siRNAs or through short hairpin RNA (shRNA) vectors. The 
first possibility is used for short-term knockdown, and normally applied directly 
into the cytoplasm. The second possibility provides the option to generate 
stable cell lines, and it is able to extend the knockdown duration. ShRNAs are 
introduced into the cell via a vehicle, either a plasmid or a viral vector. The 
chosen vector starts to express shRNAs which are further processed into 
siRNAs through the enzyme dicer [SHAN, 2010].  
In the end, it is to say, that there never will be the one and only method. All 
methods have their advantages and limitations, and it always depends on the 
approach which method is the best-suited one. Also the shRNA-mediated gene 
silencing and the siRNA-mediated gene silencing are not competing. They 
should be seen as a complement to each other [PADDISON et al., 2002]. But to 
summarize all the advantages and disadvantages of vector expressed siRNAs, 
synthetic siRNAs still represent the golden standard reagent with the broadest 
applicability [CLAYTON, 2004]. 
 
3.8.1 RNA interference through chemically synthesized siRNAs 
With the introduction of synthetic siRNAs, the whole application system of 
siRNAs into the RNAi pathway got revolutionized. The synthetic siRNAs, 
between 21 and 22 nucleotides in length, with the typical characteristics of the 
natural siRNAs, are able to initiate the degradation step without any need of the 
typical cleavage step through the enzyme dicer [ELBASHIR et al., 2001b]. The 
small interfering RNAs are able to incorporate directly into the RISC complex by 
imitating natural siRNAs and guide the target degradation step [ZAMORE, 
2001]. A positive effect was the discovery that synthetic siRNAs function as well 
in mammalian cells, by bypassing the dsRNA-dependent immunity response 
[ELBASHIR et al., 2001b]. But some drawbacks still remain. First, the later 
mentioned, transient attribute after the transfection into the cell does not allow 
48 
  
long-term approaches; second, the requirement for chemical or enzymatic 
synthesis of siRNAs before the application into the cells; third, the 
astronomically high cost of the chemical production of the synthetic siRNAs; 
and fourth, difficulties in the transfection of siRNAs into certain cell types 
[TUSCHL, 2002] [AGRAWAL et al., 2003] [KIM, 2005]. But nevertheless, 
synthetic siRNAs emerged to the method of choice for investigating gene 
function in cultured mammalian cells [PADDISON et al., 2002]. The huge 
possibility of efficient homologous degradation of the target gene, guided by 
those synthetic siRNAs, leads to high throughout approaches in mammals for 
genome wide analysis of gene functions in general, and also regarding 
modulation of gene expression in human diseases [CHI et al., 2003].  
Like already mentioned, the chemical synthesis of siRNAs is a very expensive 
effort with the disadvantage, that there is no guarantee that the first produced 
siRNA will work at all, or with the expected efficiency and specificity [SOHAIL & 
DORAN, 2005]. Normally instead of only one, several oligonucleotides need to 
be investigated first, to check which one works with the highest efficiency and 
specificity, before the target gene is successfully silenced [MYERS & FERREL, 
2005]. Naked siRNA can be applied to some tissues and organs such as eye, 
lung, and CNS through injection, instillation, or infusion and get integrated into 
the tissue by an unknown mechanism. But other cell types are not able to 
incorporate the naked siRNAs, so that other transfection methods had to be 
figured out [SHAN, 2010]. One of the most used and very effective transfer 
methods for short-term silencing is the incorporation of siRNAs into liposomes 
[MILHAVET et al., 2003]. Liposomes are coated by a bilayer of phospholipids, 
which fuse with the cell membrane and deliver the integrated molecules into the 
cytoplasm [SHAN, 2010]. Other methods like electroporation, microinjection, 
and hydrodynamic shock, also covalent binding to hydrophobic carrier 
molecules or covalent coupling to cell penetrating peptides, and bombardment 
with nucleic acid coated gold particles have evolved [MILHAVET et al., 2003] 
[WADHWA et al., 2004] [LU & WOODLE, 2005].  
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To lower the production costs and to overcome the transient problematic, many 
research centers developed alternative strategies to extend the period of 
efficient gene silencing and to establish the production of stable loss-of-function 
RNAi [WADHWA et al., 2004]. Possibilities to achieve the longer and stable 
gene silencing, is by designing DNA templates to express siRNAs 
intracellularly. As delivery agent, plasmids and viral vectors, like retroviral 
vectors and lentiviral vectors are often used, to carry short hairpin RNA 
(shRNA) into the cell [KIM, 2005]. Libraries for siRNA and shRNA-containing 
vectors, which cover entire genomes, are already developed [EIFERT et al., 
2008]. Also diverse chemically synthesized siRNAs are already available from 
several companies [LATHAM et al., 2005]. 
For in vitro experiments, bacterial or viral enzymes are used [SOHAIL & 
DORAN, 2005]. For example, purified recombinant dicer enzymes or bacterial 
RNase III enzymes can be employed to cleave large amounts of in vitro 
transcribed dsRNA. The cleavage results in a huge pool of so-called diced 
siRNAs (d-siRNAs) or endonuclease-generated short interfering RNAs 
Fig. 12 Strategies to deliver the silencing signal into the organism
[LEUNG & WHITTAKER, 2005] 
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(esiRNAs) [RAMOS-NINO & MOSSMAN, 2005]. One disadvantage of using 
those pools of RNAs is that the chance for off-target effects might be increased, 
because the chance that a mixture of a variety of siRNAs matches to more off-
targets is higher than for copies of a single siRNA [MYERS & FERREL, 2005]. 
In the beginning, it was assumed, based on facts, that synthetic siRNAs can 
easily bypass the immunity response, that the gene silencing effects are highly 
gene-specific, and no side-effects, secondary effects were actually detected 
[CHI et al., 2003]. Unfortunately the first assumption proved to be wrong. 
Chemical synthesized siRNAs are able to induce parts of the interferon pathway 
[MITTAL, 2004]. 
 
3.8.2 Short-hairpin RNA-mediated gene silencing 
One possibility of gene silencing has already been discussed. The applications 
of synthetic siRNAs, which act like products of dicer, enter directly the RISC 
complex to guide the degradation step of the target RNA. One important 
disadvantage is the transient attribute of the synthetic siRNA induced RNAi. To 
bypass that effect, an alternative strategy was developed [PADDISON & 
HANNON, 2002]. Short-hairpin RNAs are composed to down-regulate in a 
sequence-specific way the expression of the target gene. Two possible ways 
exist to induce shRNAs silencing, either by transfection of exogenously 
synthesized shRNAs or directly by in vivo transcription from RNA polymerase II 
or III promoters. Through the availability of endogenous expression of shRNAs, 
the door is now wide open for production of cell lines, in which RNA interference 
is used to stably suppress the gene expression [PADDISON et al., 2002]. A 
continuous and heritable silencing effect can be achieved, without fading away 
after a few cell divisions [MITTAL, 2004]. So the big advantage compared to 
chemical synthesized siRNAs is the continuous and stable transcription in cells, 
cultures, or in vivo [MILHAVET et al., 2003]. 
Short-hairpin RNAs adapted as effective method to trigger gene silencing in 
diverse organisms as plants, C. elegans, Drosophila m., and mammalian cell 
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lines such as HeLa cells, monkey epithelial cells, and murine fibroblasts. It 
seems so far, that shRNAs can also escape the immunity response of 
mammalian cells. That leads to the possibility to use shRNAs as tool for stable 
gene suppression in mammalian cells [PADDISON et al., 2002]. There are two 
different classes of shRNAs. Class number I represents the hairpin RNAs 
designed to work like siRNAs. The second class includes the members of 
shRNAs, which are modeled after miRNAs [McMANUS et al., 2002]. 
MicroRNAs are encoded by hairpin precursors and are further processed by 
dicer into their mature forms of ~21 nucleotides in length. There, typical natural 
characters are the imperfect base pairing, the hairpin structures including 
several bulges, and the fold-back stem-loop of around 30 nucleotides. 
Interestingly, shRNAs, which are designed to contain a simple hairpin structure 
with perfect homology to the target, are the most potent inhibitors [PADDISON 
et al., 2002]. 
In general, a few recommendations for the design of the shRNAs construct 
emerged. The duplex should contain between 19 and 30 nucleotides for the 
hairpin construct, because longer ones are often more effective than shorter 
ones. It is important to keep an eye on the orientation of the guide and the 
passenger strand [JAGLA & AULNER, 2008]. Constructs designed with Pol III 
promoter are usually designed to express first the sense strand of the siRNA, 
and then a short spacer, followed by the antisense strand of the siRNAs, and 
then terminated by a 5-6 thymidines sequence as transcription stop. The 
opposite arrangement of sense and antisense strand does not interfere with the 
potency of the transcribed shRNAs. The long use of Pol III promoters, such as 
U6 and H1, results from the facts that Pol III promoters contain a transcription 
start point and a termination point. Additional is the fact that the construct 
encode already the required uridine overhang, which is perfect for the newly 
synthesized siRNAs and the further process. But nowadays, Pol II promoters 
are recommended. Pol II promoters produce a longer and stable shRNA 
production in the cells [LATHAM et al., 2005]. With the change to Pol II 
promoters, the potency of the silencing effects was increased sufficiently 
[AULNER & JAGLA, 2008]. Especially in cells with a weak or even not visible 
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answer, Pol II promoters are the right choice to display phenotypes 
[DYKXHOORN et al., 2003]. The length of the loop (tested 4 to 23 nucleotides) 
does not interfere with the degree of the suppression. Experiments displayed 
that the silencing effect depends on the correct and stable integration of shRNA 
regarding the orientation into the genome [PADDISON et al., 2002]. The 
transfection of the construct can be achieved in different ways. All standard 
delivery methods of conventional transfection and several viral vectors, ranging 
from retroviruses to adenoviruses, can be used. The expression of the shRNA 
in vivo is either driven by constitutive or inducible promoter system [HANNON & 
ROSSI, 2004]. 
Like for every method, some advantages and limitations occur. ShRNA vectors 
are a good choice for cells which are hard to transfect or cells which cannot 
survive chemical modification [SHAN, 2010]. For very stable proteins or for 
approaches which require a continuously knock-down of the expression, this 
method is the recommended one [QUERFELLI, 2008]. In contrast to 
synthesized siRNAs, by using shRNAs the ability to control the shRNA 
expression is given [AULNER & JAGLA, 2008]. On the other hand, the level of 
gene silencing mediated by shRNAs is variable and less reproducible, and does 
not allow any control of the achieved dose for the silencing effect inside the cell, 
compared to siRNAs, where the dose to achieve an effective knockdown can be 
controlled [CLAYTON, 2004] [QUERFELLI, 2008]. Limitations are also in 
studies of genes essential for cell survival, cell-cycle regulation, and 
development. The stable down-regulation over extended periods can result in 
non-physiological, compensatory responses, which can mask the true biological 
consequence [MITTAL, 2004]. The previous work, before the actual experiment 
can be started, is a lot greater than using siRNAs. First, the DNA fragment of 
the target has to be sequenced and afterwards cloned, to produce the 
construct. Second, the design of the shRNA must be ruled out carefully to result 
in an effective and sensitive construct [HANNON & ROSSI, 2004]. But with the 
development of variety libraries for siRNAs and shRNAs, this part of the 
experimental approaches got a lot easier [AULNER & JAGLA, 2008]. 
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3.8.3 Transfection agents 
Since 2002, it is possible to transport siRNAs into various cells via DNA vectors, 
either with plasmid vectors or viral vectors [SHI, 2003]. Plasmid-based delivery 
agents express shRNAs directed by RNA polymerase III, such as U6, H1, 
snRNA, or tRNA promoters, or RNA polymerase II promoters [WADHWA et al., 
2004]. The perfectly homologous stem loop of the shRNA to the target mRNA is 
further processed by dicer into siRNA. Those siRNAs are then integrated into 
RISC to guide the degradation of mRNAs. The cost, compared to chemically 
synthesized siRNAs, is lower for plasmid-based RNAi [MITTAL, 2004]. As 
mentioned earlier, the transient effect in mammalian cells results from the 
missing amplification system. One plus of DNA-vectors is that those transient 
effects can be bypassed. As a result, a stable siRNA expression in the target 
tissue is given, and this leads further to a longer and more stable gene silencing 
effect [SHI, 2003].  
Because of some limitations of the usage of the plasmid vehicles, such as less 
potency compared with transfected siRNAs, and the difficult part of the 
transfection in general, viral vectors were developed [AGRAWAL et al., 2003]. 
Using the viral transfection agents, an increased efficiency, regarding the 
transfection of the cells, was achieved. Also a longer and even more stable 
gene silencing in vivo of the targeted gene was gained with the employment of 
viral vectors [MILHAVET et al., 2003]. Different kinds of viral vectors are 
developed; retroviral, lentiviral, and adenoviral vectors were used to deliver 
siRNAs into cells and tissues, which are difficult to transfect with other methods 
[WADHWA et al., 2004]. One attribute of the adenovirus is that they do not 
integrate into the host genome. This actually, makes it to a more suitable 
transport system for RNAi-based gene therapy in humans [MITTAL, 2004]. 
They are non-enveloped DNA viruses and contain a large and complex genome 
structure. They can be successfully transfected into cells, which are hardly to 
transfect with standard methods. Characteristics of the retroviral-vector are the 
small and simple genome structure. So it is quite easy to clone the gene of 
interest into the vector. After that production step, it is fast to amplify the vector. 
Retroviruses can target only dividing cells and can be integrated into the 
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genome. Their characteristic, to be an enveloped virus, is valuable. It is easy to 
change the target, only the envelope has to change. Retroviral-delivery agents 
are best suited to build libraries [MAO et al., 2005]. Lentivirus, a subclass of the 
retroviral viruses, possesses the ability to get efficiently integrated into the host 
genome of non-dividing cells, like stem cells or terminally differentiated cells 
[MITTAL, 2004]. 
A limitation turned out to be that viral-agents have to be injected locally and 
cannot target individual tissues. Another option would be the sampling of some 
cells and after ex vivo treatment the cells get replaced [CLAYTON, 2004]. 
Recently published studies indicate that it is now possible to inject the virus-
vector straightforward into the target tissue or organ [SHAN, 2010]. All the 
positive effects of the viral-agents are clouded though the concerns, that the 
integration of the viral structure into certain genomic locations might lead to 
pathogenic gene expression or that the expression of viral proteins leads to 
negative biological effects for the host organism. Altogether, non-viral vectors 
are the safer choice for therapeutic treatment [LU & WOODLE, 2005].  
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Fig. 13 Strategies for siRNA production in vivo and in vitro
SiRNAs can be synthesized in vitro and afterwards transfected into the cell (A,B or F), produced in vivo from 
DNA templates (C,D, or E), or derive from hairpin precursor (C, E). [MYERS & FERREL, 2005] 
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3.9 Advantages and limitations of the RNA interference mechanism  
Already in the early days of the newly discovered method, a very high potency 
was expected for further research in a wide variety of organisms and different 
fields [HUNTER, 1999]. Theoretically every expression of every gene can be 
inhibited; the better suited term would be down-regulated [NIRENBERG, 2005] 
[MAINE, 2001]. This newly discovered method may open the doors to a new 
class of drugs to treat a variety of human diseases. Because of the astonishing 
sequence specificity, the possibility to identify and validate new drug targets, 
and design sequence-specific drugs, RNAi arose to the method of choice for 
drug targeting and pathway validation [SEMIZAROV et al., 2003]. RNA 
interference developed into the method of choice, to investigate gene functions, 
to identify cloned genes, determine loss-of-function phenotypes of genes 
without known mutations, and creation of null mutant phenotypes of specific 
genes, and in vivo target validation in C. elegans and later in Drosophila 
melanogaster [HUNTER, 1999] [NISHIKURA, 2001]. With the discovery that the 
introduction of siRNA into mammalian cells leads to an efficient and robust 
silencing effect, hardly any boundaries exist for the mechanism [PADDISON et 
al., 2002]. Nowadays it is already possible to buy RNA production kits 
[SCHEPERS, 2005].  
RNAi provide a simpler way to study gene functions, especially regarding genes 
essential for viability or genes expressed in maternal germline in C. elegans, but 
RNAi does not supersede classical genetics in the nematode [BARSTEAD, 
2001]. In species, which are not amenable to genetic analysis, RNAi proved 
especially useful, because with RNAi the possibility emerged to knock-down the 
gene expression of diverse genes [BOSHER & LABOUESSE, 2000]. One 
advantage compared to classical forward genetics is, that lethal null-mutant 
phenotypes, which are missing in classical forward genetics, can be identified in 
RNAi screens [POULIN et al., 2004]. A very handy characteristic is that the 
maternal and zygotic gene function is simultaneously inhibited [HUNTER 1999]. 
RNAi is a very practical tool to investigate gene function in a wide variety of 
organisms. But it is important to keep in mind, that both methods, the classical 
forward genetic and RNAi are not competing, they complete each other and 
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none of them can supersede the other one [FRASER et al., 2000]. The ability of 
RNAi, to be used for large-scale and whole-genome screens should not be 
unmentioned. It can be used, for example, to investigate all genes necessary for 
a certain physiological pathway. In general, a whole-genome screen can be 
carried out for every biological process [LEUNG & WHITTAKER, 2005]. Large-
scale screens of loss-of-function experiments provide important information 
about pathways involved in development of diseases. This information can be 
further used for research and development of therapeutics, especially for those 
classified targets [APPASANI, 2005]. 
RNA interference is an easy to use method, especially for organisms with a 
complete sequenced genome. And it is an inexpensive and rapid method to 
analyze gene functions in a variety of organisms [TUSCHL, 2001] 
[DYKXHOORN et al., 2003]. Approaches in liquid cultures can be carried out 
easily by one person [POULIN et al., 2004]. It would take months to years to 
clone all the genes by classical forward genetics, responsible for all the mutant 
phenotypes, while RNAi can deliver the results in about a month [SUGIMOTO, 
2004]. For example, to generate a knock-down mouse, it is required to insert a 
single transgene. First, a part of the gene on both chromosomes has to be 
removed. Afterwards, the silenced type can be generated in just a few months 
of work. In contrast to produce knockout mice, this would take a few years 
[DYKXHOORN & LIEBERMAN, 2005].  
One of the biggest pluses is the possibility to connect already known gene 
sequences to their phenotypes/functions and the unbelievable speed of the 
possibility to investigate all those new phenotypes [BARSTEAD, 2001]. There 
are two different approaches to work with. First is to silence one gene after the 
next, so the identification of molecular parts of specific pathways and processes 
is possible [FRASER & AHRINGER, 2003]. The second one is to collect all data 
of every phenotype in a systematic way [SUGIMOTO, 2004]. 
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RNAi is not a method without limitations. With an RNAi approach, never a 
complete knock-down can be achieved. It is rather a gene knock-down than a 
gene knock-out phenomenon [DYKXHOORN & LIEBERMAN, 2005]. It is a fact, 
that RNAi-based screens miss some related genes, because of the drawback; 
RNA interference does not inhibit all gene expressions [FRASER et al., 2000]. 
The diminution of the mRNA levels is required at a critical threshold to display 
the resulting phenotypes. This rate depends on factors, such as the balance 
between dsRNA mediated mRNA destruction and de novo mRNA synthesis, the 
natural stability of the mRNA, or the dsRNA uptake and further processing, and 
the availability of the RNAi machinery [TIMMONS et al., 2001]. This results in 
that; RNA interference does not necessarily display always visible phenotypes 
or express phenotypes with the same intensity [KUMABARA & COULSON, 
2000]. And this might lead to false-negative results [MITTAL, 2004]. Also the 
only way to respond to RNAi is with a loss-of-function phenotype. Compared 
with other methods, like usage of mutagens, they are able to display gain-of-
function and partial loss-of-function phenotypes too [JOHNSON et al., 2009]. 
Another difficult part is that not all tissues answer with the same efficient 
response, for example the nervous system is mainly refractory to the 
phenomenon and sperms occur to be not very sensitive [KUMABARA & 
COULSON, 2000]. This implicates, that genes with essential functions in 
neuronal tissue are most likely missed in RNAi screens [SUGIMOTO, 2004].  
One of the biggest challenges is to overcome the cross-interference between 
closely related sequences or in gene families, and to avoid off-target effects in 
general [KUMABARA & COULSON, 2000]. Sequences which are partly equal, 
with an only trigger-target identity of 80%, can be inhibited [MAINE, 2001]. This 
affects especially sequences of related genes or gene family. This results in 
that, the interference effect can be triggered also in the related, not-targeted 
genes [FIRE et al., 1998]. Most of the off-targets are concentration dependent, 
so researchers try to achieve efficient effect with the lowest possible dose 
[VANHECKE & JANITZ, 2005]. So far, the only recommendations are to work 
with the lowest possible dose and to select sequences which share as little 
homology with other mRNAs as possible. If off-target effects are expected, 
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alternative trigger sequences of the target should be chosen [JOHNSON et al., 
2009]. Another side effect of the RNAi response in mammalian cells is the 
activation of an interferon pathway. This problem has already been discussed in 
chapter 3.6, difficulties for RNA interference in mammals. Also the transient 
RNAi, including the generation of secondary siRNAs should not be missed at 
this place. The secondary siRNAs, containing a bit different sequence 
configuration, may lead to phenotypes not specific for the actual silenced gene 
[CHI et al., 2003]. 
There are also some problems with the reliability of the results. RNAi results 
from the same experiment design executed from different research groups, but 
also experiments executed in the same laboratory, showed a variability of 10% 
to 30%. This is explained by an extreme highly false negative rate in every 
RNAi screen. And it does not matter, if the same laboratory or the same 
experimental designs, including the same conditions, are used [SIMMER et al., 
2003]. Some conditions, which might influence the results, are slight differences 
in the timing regarding the developmental stages of the nematode, length of 
exposure to the trigger RNA, used concentrations of dsRNA, and fluctuation of 
temperature during the experiment [SUGIMOTO, 2004]. 
An important thought is that it is unknown, how the introduced siRNAs, either 
the synthetic ones or the siRNA expressing vectors, will interfere with the RNAi 
machinery. RNAi emerged as a natural mechanism, and is required in so many 
pathways, that it is not known what will happen if the mechanism gets 
kidnapped. Till now, there is no evidence that there are any negative impacts on 
the processing, regulation of the natural process regarding endogenous siRNAs 
and of course miRNAs, beside the mentioned side effects [CHI et al., 2003]. 
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3.9.1 Off-target effects 
Actually, the first suggestions for cross-silencing were reported already in the 
first year of the discovery of RNAi in C. elegans [TABARA et al., 1998]. The 
idea emerged that dsRNA corresponding to a gene in an “operon” may be able 
to silence other co-transcribed genes too [MAINE, 2001]. But for long time, 
there was no consistent off-target effect displayed by siRNA-mediated RNAi. 
The synthesized siRNAs occurred to be highly sequence specific, and seemed 
to target only the mRNA of interest [CHI et al., 2003]. But evidence showed that 
the fear of RNAi not being perfectly specific, came true. For long time, 
researchers thought that the generated siRNAs are undeniable specific. There 
was no proof, that for example 17 nucleotides out of 21 from a siRNA can 
trigger off-target effects [COUZIN, 2004]. But evidence displayed already off-
target effects with siRNAs containing 11 consecutive nucleotides homologous to 
another mRNA [AULNER & JAGLA, 2008]. The picture changed with the ability 
to induce RNAi in mammalian cells with synthesized siRNAs [COUZIN, 2004]. 
From this moment on, it was confirmed that siRNAs are able to guide gene 
silencing without a complete corresponding sequence [QIU et al., 2005]. 
Introduction of siRNAs resulted not only in the expected down-regulation of the 
targeted gene; instead a down-regulation of multiple genes was displayed. The 
first evidence for the ability of siRNAs to “cross-react” was demonstrated. 
Endogenous miRNAs, are similar in size, but are not perfect complementary to 
their targets and match only partly. It was figured out, that hundreds of miRNAs 
play an important role in diverse pathways of the mammalian organisms by 
using some parts of the RNAi machinery. The introduced siRNAs are mistaken, 
and thought to be endogenous miRNAs, which results in the unwanted off-
target effects. Off-target effects are visible under microarrays analysis, with the 
huge disadvantage that microarrays display only the gene expression, but do 
not say anything about the protein levels [COUZIN, 2004]. The main problem of 
negative results is, that the protein levels could be, after the gene silencing, still 
low, but high enough to trigger the natural function without any negative 
consequences for the organism and without any phenotype displayed [FRASER 
& AHRINGER, 2003]. Possibilities for negative and positive controls are at the 
61 
  
mRNA levels, microarrays, northern plot, and real-time PCR and to check on 
protein levels, western plot can be executed [SHAN, 2010].  
Off-targets effects can be classified into sequence-specific and non-specific 
effects. Knock-down or influence of the expression from a sequence-related 
gene or from a gene family member is counted into sequence-specific off-target 
effects [SEMIZAROV et al., 2003]. Non-specific effects are, for example, the 
linking of siRNAs to cellular proteins, activation of apoptosis and stress-
response genes, activation of an interferon response, or translational silencing 
through a miRNA effect [SEMIZAROV et al., 2003] [JACKSON & LINSLEY, 
2004]. To explain the side effects on the level of translation, it seems that 
siRNAs are wrongly recognized from the cell/organism as endogenous miRNA 
[JACKSON & LINSLEY, 2004]. It also might be possible that introduced siRNAs 
have such a widespread effect like changes in gene expression [SEMIZAROV 
et al., 2003]. 
The idea arose, that the off-target effects might be concentration dependent. To 
determine the critical threshold, researchers experimented with different siRNA 
concentration. With concentrations of 100nM, every tested siRNA triggered a 4 
to 8-fold increased activation of gene expression, including activation of 
apoptosis related genes. In contrast to the experiments with concentrations of 
5nM or 20nM, silencing was triggered with an equal potency compared to 
100nM, but no statistically significant side effects were measured. Because of 
that result it is suggested, that with the proper design of siRNA and a low-
concentration introduction-dose, no off-target effects should be triggered 
[SEMIZAROV et al., 2003]. Some studies also explain the high doses as toxic 
for the organism, and this toxic overdose results in the displayed off-target 
effects [JACKSON & LINSLEY, 2004]. A second factor is the length of the 
trigger dsRNA. It was demonstrated that siRNAs of 21 nucleotides in length are 
the optimal size. The probability for side-effects, increase with the length of the 
dsRNA. In general, the chance for side-effects is significantly lower for 21nt-
long siRNAs, than for shorter or longer (100-400nt) ones. Another fact to 
consider regarding off-targets is the size of the genome. The length of the 
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original introduced dsRNA has more severe influence in larger, more complex 
genomes, than in more basic ones [QIU et al., 2005]. 
In the end, the unlimited use of siRNA is not unlimited at all, like hoped in the 
first place [SEMIZAROV et al., 2003]. It is still not clear, how widespread those 
off-target effects are, and researchers are struggling with the perfect solution to 
avoid those effects [COUZIN, 2004]. The design of the synthesized siRNAs has 
to be executed very carefully. The golden goal is to maximize the knock-down 
effect by using the lowest possible siRNA concentration, and to minimize/avoid 
all cross-reactions, and off-target effects [LEUNG & WHITTAKER, 2005]. For 
interpretation of the results, it must be considered, that the displayed phenotype 
could be evoked by the side effects [SEMIZAROV et al., 2003]. But it is not 
necessary, that off-targets disturb the phenotype [COUZIN, 2004]. In fact, the 
high potential of this pretty young discovered tool is unmatched for identification 
of gene functions, that the possibilities of off-target effects must be tolerated 
[JACKSON & LINSLEY, 2004].  
 
3.10 Outlook 
In 2003, the expectations for clinical trials were that they might not start until 
2008, or even more likely 2013 [HOWARD, 2003]. But actually, the way for 
application of siRNAs as novel drugs and genetic therapy proved to be much 
longer and harder than first expected [MILHAVET et al., 2003]. With an 
optimized transfection method, perfectly designed and effective 
siRNAs/shRNAs, and the right amount of transfection agent, the dream of the 
individual gene therapy might come true soon [AULNER & JAGLA, 2008]. 
In general, the siRNA-based treatments proved to be very potent in the fight 
against diseases like cancer, infectious diseases, cardiovascular, 
cerebrovascular, and neurodegenerative diseases, but a lot of challenges have 
to be solved first [MILHAVET et al., 2003]. The delivery of siRNA into the patient 
and his/her proper tissue still remains a problem. Chemical modifications and 
proper siRNA design are figured out so far to avoid immune-stimulation or more 
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exact, to get only an acceptable level of the immune response. Other main 
causes for modifications are to safe siRNAs from the fast degradation through 
nucleases and to avoid cross-effects. Another concern is that through the 
hijacking of the machinery through exogenous introduced siRNAs, the natural 
endogenous function might be unattended, which might result in still unknown 
factors. The required dose of siRNAs still needs to get reduced, and at the 
same time the effective period needs to get increased [SHAN, 2010].  
At last it remains to say, that there is still much to discover and a lot of 
unanswered question remain [SHAN, 2010]. 
 
3.10.1 The use of RNAi in the development of novel drugs  
Already early arose the idea of using siRNA-mediated silencing as therapeutic 
agent for gene therapy, and developing novel drugs, specific for individual 
weaknesses. But the way of achieving this goal is long and rich of drawbacks 
[TUSCHL & BORKHARDT, 2002]. The variety of treatments is nearly unlimited, 
the trigger is quite easy to synthesize, and the cost for the production of the 
therapeutics are amenable. With this background and the characteristics of 
siRNAs themselves, they developed into a very eye-catching class of small-
molecule drugs [DYKXHOORN & LIEBERMAN, 2005]. For the future, it seems 
most likely to use RNAi-based drugs to treat diverse human diseases. We just 
do not know now, how long we have to wait for it [HANNON & ROSSI, 2004].  
Before this will happen, some challenges have to be overcome first. As 
mentioned, the method would be ideal, if it would not display side effects like 
the introduction of an immune response and the off-target effects [COUZIN, 
2004]. But it seems most likely, that with diverse modifications like increasing 
the stability, and bioavailability as well as adjustments, this problem can be 
solved. More information about the design of siRNAs is provided in the chapter 
3.7.2., parameters for the design of small interfering RNAs [HANNON & ROSSI, 
2004]. Another two problems are the delivery in general and the delivery of an 
effective therapeutically concentration. It depends largely on the development of 
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an efficient in vivo transport system for siRNAs, if the novel-drug will be 
successful in the future or not [LU & WOODLE, 2005]. As already mentioned, in 
high concentrations, siRNAs trigger an interferon response. So the lowest 
effective concentration should be applied [DYKXHOORN & LIEBERMAN, 
2005]. Some concerns include the use of viral vectors and the possible toxicity 
potential of the method [HANNON & ROSSI, 2004]. Through the high sequence 
specificity of siRNAs, the concerns arose, that through mutations of the 
sequence, the organisms might become resistant to the treatment. This fact can 
only be bypassed with the introduction of a new designed siRNA, which targets 
a different site of the same target mRNA [DYKXHOORN & LIEBERMAN, 2005].  
The advantage of RNAi compared to methods like antisense, ribozymes, or 
aptamers is that RNAi is a natural process, developed, established, and brought 
to perfection over thousands of years of evolution. It is not a method developed 
in the lab, where an unknown chemically synthesized intruder enters the cell. 
The opposite is the truth, nearly every cell/tissue of the organism is able to 
perform this process, is familiar to all components of the pathway, and 
theoretically all genes can get silenced [HOWARD, 2003]. 
Some of the first preclinical studies, performed with RNAi as investigation tool, 
were diseases like cancer, infectious, and viral diseases like human 
immunodeficiency virus (HIV) and hepatitis C (HCV) as well as cardiovascular 
and cerebrovascular diseases, and neurodegenerative disorders. Other 
important targets for RNAi would be autoimmune disorders, and nutrition 
associated diseases like obesity and diabetes, or in general diverse oncogenes, 
growth factors, and single nucleotide polymorphisms (SNP) [MILHAVET et al., 
2003] [HANNON & ROSSI, 2004]. More and more published papers summarize 
their results of in vivo RNAi-mediated silencing in cancer, HIV, HCV, or acute 
respiratory syndrome [LEUNG & WHITTAKER, 2005]. Actually, HIV was one of 
the first viral diseases, targeted by RNAi. The inhibition of HIV-encoded RNAs 
was achieved in cell cultures. But for therapeutic application there are some 
challenges which have to be solved first, like the delivery, the high mutation rate 
of the virus itself, and the same appearance of the toxic side effects like using 
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anti-retroviral drugs as treatment. Also in HCV, a significant knock-down of 99% 
of the main antigene could be achieved in liver hepatocytes. But also here, the 
delivery strategies, siRNAs or shRNA vectors, remain a big challenge 
[HANNON & ROSSI, 2004]. Recently, clinical trials started for treatments of 
macular degenerations, diabetic retinopathy, and hepatitis C. [SHAN, 2010].  
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4. RNA interference in the model organism Caenorhabditis 
elegans 
 
4.1 Introduction of Caenorhabditis elegans as model organism 
In nature, C. elegans, named after its elegant simplicity, lives in soil, nearly in all 
different temperate parts of the world [MELLO, 2007] [HOPE, 1999 reprinted 
2005]. This organism is frugal; as food source serve microorganisms like 
bacteria. Next to the food, humid environment, ambient temperature, and 
atmospheric oxygen are needed for development and fertility [HOPE, 1999 
reprinted 2005]. The nematode C. elegans developed into a very popular model 
organism after S. Brenner introduced the worm as new model in 1974. The 
worm is divided into two sexual forms, males and hermaphrodites. The 
hermaphrodites produce both eggs and sperms, which results in the ability of 
self-fertilization. The other possibility is to mate with a male, which produce only 
sperm, to produce offspring [BRENNER, 1974]. As a result after self-
fertilization, around 300 worms are produced, compared with mating with a 
male nematode, which results in a more than 3-fold higher number of offspring 
[BÜRGLIN et al., 1998]. It also generates males and hermaphrodites in equal 
numbers. In contrast to self-fertilization of hermaphrodites where all of the 
offspring exhibit the XX gender. One attractive characteristic for using C. 
elegans is the automatic generation of homozygous individuals through the self-
fertilization from hermaphrodites [HOPE, 1999 reprinted 2005]. In the 
configuration of the genome only one big difference appears in the gender-
chromosome. Both, male and hermaphrodite possess five autosomes and one 
sex-chromosome. Males contain only one X (for males X0) and hermaphrodites 
contain two X (for hermaphrodites XX) [BRENNER, 1974]. There are only small 
differences between the two genders; adult males are a bit shorter and thinner 
than the adult hermaphrodite [HOPE, 1999 reprinted 2005]. The anatomy of the 
multicellular organism is well characterized and the numbers of cells are fixed. 
The analyses are already that far, that the cell lineage is known from every 
developed cell [MAINE, 2001]. An adult hermaphrodite contains 959 somatic 
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cells and an adult male has 1,031 somatic cells [BÜRGLIN et al., 1998]. The 
nervous system, quite simple, is composed of 302 neurons in both genders. 
Another amazing thing is the transparency of the worm through all 
developmental stages, which allows an uninterrupted observation of every 
second of the organogenesis, and all other developmental steps of the worm 
[BARGMANN, 1993]. Another nice negligibility is that there is no appreciable 
smell [HOPE, 1999 reprinted 2005]. 
The development of the nematode is regulated through environmental 
conditions. Under special environmental conditions like food shortage, extreme 
temperature or high density, an alternative pathway gets started, referred to as 
dauer larva. If, for example, after food shortage, enough food is available again, 
the worm starts to recover and grow into the adult animal [BARGMANN, 1993]. 
In contrast to the standard lifespan of an adult worm of 15 to 17 days, animals 
Fig. 14 Life cycle of C. elegans at 22°C 
[HALL & ALTUN, 2008] 
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changed into the dauer larvae stage, and can survive in this condition several 
months [BÜRGLIN et al., 1998]. The big advantages of this organism of being 
an amazing model organism are numerous. The life cycle takes about three and 
a half days, at 20°C, three days at about 25°C, or around 6 days at 15°C to 
pass all 4 larvae stages, L1-L4, and grow into an adult worm [BRENNER, 1974] 
[BARGMANN, 1993] [HOPE, 1999 reprinted 2005]. After 14 hours, at 25°C the 
embryogenesis is completed [BARGMANN, 1993]. To pass all 4 larvae stages, 
L1-L4, and grow into an adult worm, 12h for the L1, 8h for L2, 8h for stage 3, 10 
hours for L4 and another 8 hours to develop into a young adult must be 
calculated [HALL & ALTUN, 2008]. The short generation time allows genetic 
approaches with follow-ups over multiple generations [KUWABARA & O'NEIL, 
2001].  
The easy handling of C. elegans helped to integrate the nematode as model 
organism too. C. elegans can be cultured either on agar plates, in liquid culture, 
or on axenic media as alternative [KUWABARA & O'NEIL, 2001]. These are 
very cheap and easy methods to culture the worm in the lab. Contaminations 
with other bacteria, mold, or yeast, do not hurt the nematodes, but bother the 
experiments especially to score the phenotypes. Actually, it seems that the 
worms like to swing on the roots of the mold. To get rid of the contaminations, it 
can be cleared by using bleach. Eggs survive the bleaching treatment 
[STIERNAGLE, 1999 reprinted 2005]. To the easy handling counts also the 
food source, E. coli OP50 bacteria. Also the small size about 1mm length is a 
huge advantage regarding the space problem. Because of their small size, 
thousands of worms can be cultured and stored easily. The discovery from J. 
Sulston, that the worm can be frozen for longer time in liquid nitrogen (-196°C), 
was also very helpful to culture the worm in the laboratory. Especially worms in 
early larval stage (L1 & L2) survive freezing and defrosting very well, in contrast 
to eggs, which do not survive [BRENNER, 1974]. Another possibility next to 
freezing in liquid nitrogen is storing worms at -70°C [BÜRGLIN et al., 1998]. The 
recovering rate of 35 to 45% of worms stored in liquid nitrogen is a lot better 
compared to the second method with a success rate of around 10%. Also to 
mention is, that not all strains are able to freeze, some mutants do not survive 
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the freezing at all. Nowadays, it is possible to order either wild-type strains or 
the required mutant strains of the diverse choice of mutant strains from the 
Caenorhabditis Genetics Center [STIERNAGLE, 1999 reprinted 2005]. More 
information about how to order strains is given on their homepage [University Of 
Minnesota, 2011]. Also the databases wormbook as well as wormbase provide 
an up-to date information source [WormBook, 2010] [POULIN et al., 2004]. 
Another good reason for the use of the nematode as model is the small size 
and simplicity of the genome [BÜRGLIN et al., 1998]. Also a plus is that the 
nematode C. elegans was the first metazoan with a fully sequenced genome, 
with first predicted 18,972 genes, and actually 19.762 genes [KIM, 2001] 
[SCHWARZ, 2005]. Only because of the now known genetic sequence of the 
worm, a door with so many different possibilities got opened, like the 
investigation of functions of genes in general, and whole-genome screenings 
via RNAi [FRASER & AHRINGER, 2003]. Early assumptions indicated that that 
about 74% of the human genome have homologous matches in the nematode 
[KUWABARA & O'NEIL, 2001]. So far, homologies for around 50% of all genes 
in C. elegans were found in humans [KAMATH et al., 2003]. This fact made C. 
elegans a perfect model to investigate developing errors, malfunction of the 
metabolism, and various diseases [KUWABARA & O'NEIL, 2001].  
All those characteristics made the worm a perfect model organism for genetic 
studies, molecular assays, and biological approaches [KUWABARA & O'NEIL, 
2001]. 
 
4.2 RNA interference in Caenorhabditis elegans  
C. elegans is the first animal where RNAi was discovered. And this was only a 
few years ago, and RNAi emerged rapid into a frequently used tool 
[DYKXHOORN et al., 2003]. Nematodes proved as a very useful model 
organism for the first steps of the investigations. Another big advantage for C. 
elegans, to be employed as a very potent model organism is, not only the 
already mentioned advantages, also a huge collection of diverse mutations of 
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the genome exists [SUGIMOTO, 2004]. RNAi is simple and most effective in the 
nematode. A highly specific mechanism, targeting only genes homologous to 
the origin, introduced RNA sequence [MONTGOMERY et al., 1998]. It does not 
affect the gene expression at all, and no gene damage or genetic alterations are 
found [TUSCHL et al., 1999]. RNAi was used in C. elegans to verify 
homologous genes in different species, to investigate unknown gene functions 
in vitro and in vivo, and to complement the classical forward genetic method 
[MAINE, 2001]. Through the development of large genome libraries of RNAi 
clones, it got possible for large-scale approaches to screen the entire genome 
for the genes of interest [JOHNSON et al., 2009]. And RNAi sensitive strains 
like rrf-3 mutants made it possible to screen in tissues, which display normally 
no phenotypes in the wild-type [STEPHENS et al., 2005]. An interesting fact is 
that around 50% of all genes in C. elegans were found to have a human 
homologue [KAMATH et al., 2003]. And for about 75% of the genes, which are 
known to be employed in the development of disease in humans, were found to 
have homologues in the worm [STEPHENS et al., 2005]. 
Like mentioned, the misbelieve that single-stranded RNA can induce a fully 
RNAi response was soon overcome [FIRE et al., 1998]. Double-stranded RNA 
produces a strong and effective RNAi response in C. elegans and does not 
trigger any activation of the PKR-pathway or other immune response at all 
[FISCHER, 2010]. In general, RNA sequences of about 200 to 1,000 
nucleotides, or even longer ones, are able to trigger an RNAi response 
[TABARA et al., 1998]. The effect requires the homology of at least 80% 
between the exogenous trigger dsRNA and the endogenous mRNA [KAMATH 
& AHRINGER, 2003]. RNAi starts after the introduction of long dsRNA. Long 
dsRNA gets cleaved by the ATP-dependent RNase III enzyme dicer into 21-
25nt long RNA-fragments, siRNAs [HUTVÁGNER & ZAMORE, 2002]. Through 
the cleavage the characteristic structures of the 5’- and 3’ end of siRNAs are 
generated [CAPLEN et al., 2001]. After the incorporation of the single-stranded 
siRNA into RISC, siRNA guides the whole complex to the homologous mRNA, 
recognizes the complement, and initiates the degradation [HUTVÁGNER & 
72 
  
ZAMORE, 2002]. Also the silencing effect at the translational level occurs in C. 
elegans [VASTENHOUW & PLASTERK, 2004]. 
In the first studies, performed at C. elegans, dsRNA was injected into the 
gonads or the body cave. Later on, it was discovered that feeding dsRNA 
expressing bacteria or even soaking by a high-concentrated dsRNA solution 
induces RNAi [GRISHOK, 2005b]. The resulting phenotype can be very strong 
and specific and look alike null-mutations of the gene. But also phenotypes can 
appear weaker [TABARA et al., 1998]. It has to be mentioned, that RNAi-
phenotypes can never be counted as null-mutant phenotypes, because the 
mRNA is only for limited time degraded and never fully eliminated [MAINE, 
2001]. Sometimes an affected gene displays even more than just one 
phenotype. This happens, if the gene is involved in more than just one function. 
Typically, highly conserved genes are more affected to induce an RNAi 
response than non-conserved genes [FRASER et al., 2000]. It should be 
mentioned, that the time between the treatment and the appearance of the 
phenotype is variable. It depends quite a bit on the stability of the protein, 
because every single one has to be degraded first, before the phenotype gets 
visible [MAINE, 2001]. Not all genes and tissues react with the same sensitivity. 
It seems that the neuronal tissue is nearly total refractory to the RNAi effect. 
The phenotype displayed can differ from animal to animal and appears not 
always at the same intensity. The mentioned cross-effects occur also in C. 
elegans, if a certain amount of sequence homology is given [KAMATH & 
AHRINGER, 2003]. 
Today, an enormous amount of different C. elegans strains are available at the 
Caenorhabditis Genetics Center. For regular approaches, the wild-type strain 
Bristol N2, introduced from S. Brenner is used. But as mentioned, sometimes a 
more sensitive strain is required [SCHEPERS, 2005].  
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4.3 Specialties of the RNA interference mechanism in Caenorhabditis 
elegans 
The RNAi effect provides in C. elegans some specialties, which are not 
developed in every other organism, such as systemic RNAi, inheritance of the 
RNAi effect, amplification of the signal, and the generation of secondary 
siRNAs, while the core components are conserved through a variety of 
organisms [SUGIMOTO, 2005]. 
 
4.3.1 Systemic RNAi 
It was already seen early, that dsRNA-mediated gene silencing possesses the 
ability to travel across the cellular boundaries [FIRE et al., 1998]. In fact, 
systemic RNAi gets implicated as an antiviral-defense mechanism and against 
environmental pathogens, contaminations of growth media [SCHEPERS, 2005]. 
The gene silencing effects stays highly sequence-specific through the spreading 
process. So far, the spreading mechanism is well established in plants, 
planarias, and C. elegans, but not at all in flies or mammals [AGRAWAL et al., 
2003] [TIJSTERMAN et al., 2004]. The phenomenon observed in plants was 
named systemic acquired silencing (SAS) [SIJEN & KOOTER, 2000]. In plants, 
the signal spreads via plasmodesmata to the neighbor cells, and to other parts, 
further away, through the phloem [AGRAWAL et al., 2003].  
Spreading in nematodes was observed the first time, after the mistaken 
injection of dsRNA into the body cavity instead of the germline [GRISHOK, 
2005b]. This indicated that one distribution pathway in higher animals of dsRNA 
works via the ceolomic fluid [SCHEPERS, 2005]. Nowadays, there is enough 
prove, that exposure of the nematode to dsRNA in anyway, either by soaking, 
feeding, or injection, leads to the expected systemic effect [TIMMONS et al., 
2001]. The effect is not limited to neighbor cells at all. The signal can spread to 
another differentiated tissue far away from the part of the original injection 
[TIJSTERMAN et al., 2002]. The signal has also the possibility to trigger the 
silencing effect in the next several generations [AGRAWAL et al., 2003]. 
Important to consider is, that the inheritance further than to F1, occurs only if 
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genes in the germline are targeted. In general, the silencing effect in the F1 
generation is more efficient than in the parents [GRISHOK, 2005b]. Also it is 
displayed that the spreading effect is stronger by feeding or soaking then by 
injection of dsRNA [TIMMONS et al., 2001]. And injection into the intestine is, 
by far, the most effective method [GRISHOK, 2005b]. 
Sid-mutants and rsd-mutants are animals which lack the phenomenon of 
spreading [TIJSTERMAN et al., 2002] [TIJSTERMAN et al., 2004]. Sid-1 
mutants display no other phenotype than the defect to spread through the 
animals. And as a result they are not able to inherit the silencing signal to their 
progeny [AGRAWAL et al., 2003]. SID-1 is proved to be required for systemic 
RNAi. It encodes a transmembrane protein, working by an active transport via a 
sort of receptor or channel [TIMMONS et al., 2003] [AGRAWAL et al., 2003]. 
The exact transportation of the signal remains unknown [BERNSTEIN et al., 
2001]. The explanation for the lack of systemic RNAi in mammals might be the 
fact that only closely related homologous of rsd-3 was found [TIJSTERMAN et 
al., 2004]. There are no homologous of sid-1 in Drosophila, which explains the 
lack of the mechanism [AGRAWAL et al., 2003]. There exists no systemic 
response in neuronal tissues, because of the missing expression of sid-1 
[SCHEPERS, 2005]. It seems that the whole systemic silencing pathway is 
highly complex and might be tissue-specific [TIMMONS et al., 2003]. 
Suggestions indicate that the whole system contains more than one transport 
mechanism for cellular uptake [SCHEPERS, 2005].  
A recently published study implicated next to sid-1 also rsd-2, rsd-3, and rsd-6 
as required genes for systemic gene silencing from the soma to the germline 
[FISCHER, 2010]. 
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4.3.2 Inheritance 
Another specialty of C. elegans, which is not given in every other organism, is 
the ability of the RNAi effect to get passed on to the next generation [FIRE et 
al., 1998]. And not only the next generation, is able to show the RNAi effect. 
The effect is also stable inherited into further progeny [COGONI & MACINO, 
2000]. The inheritable effect causes no alterations of the genomic structure of 
the target sequence. Especially sensitive, for the entire RNAi phenomenon, are 
the genes encoded in the germline. That results in phenotypes which are 
displayed for several generations. The RNAi effect, which is passed on to the 
F1 generation only, can be explained by the persistence of the signal [TUSCHL, 
2001]. While long-lasting RNAi is adopted as heritable and requires the 
formation of an inherited agent first, this is based on the RNAi genes rde-1 and 
rde-4 [TIJSTERMAN et al., 2002]. After the formation, the agent is passed on 
extra-chromosomally, through sperm or egg. In the second step, the transferred 
agent must initiate an RNAi response in the second generation [KETTING et al., 
2003]. Now, rde-2, rde-3, and mut-7, which are not required to inherit the RNAi, 
are required for the persistence of the RNAi effect in general and rde-1 and rde-
4 are no longer needed [ZAMORE et al., 2000]. Recent studies also found more 
factors for inheritance to depend on several chromatin remodeling factors such 
as isw-1, mrg-1, and hda-1 [FISCHER, 2010]. 
 
 
 
Fig. 15 Generation of an inherited agent through RDE-1 and RDE-4 and persistence of the silencing
signal trough RDE-2 and MUT-7 
[TIJSTERMAN et al., 2002] 
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4.3.3 Amplification / RNA-dependent RNA polymerase 
The fact, that injected dsRNA into the nematode does not act stoichiometrically 
and only a few molecules can trigger an effective RNAi response, arose the 
idea of an amplification pathway and/or catalytic step [MONTGOMERY et al., 
1998]. It is most likely that both effects play their part in RNAi, but not 
necessarily in all organisms [SHARP, 1999].  
It should be noted, that more than one factor is involved to amplify the signal. 
Some degree of amplification is achieved through the cleavage of the 500 to 
1,000 basepair long dsRNA into a larger amount of 21-23 nucleotide long 
siRNAs. Results showed, after the cleavage, a 20 to 40-fold increased molar 
level of the trigger RNA compared to the target [SIJEN et al., 2001]. But this 
mechanism alone cannot explain the extreme high potency and persistence of 
RNA interference, and the ability for systemic RNAi [AHLQUIST, 2002]. Another 
explanation would be a very efficient and highly catalytic process by the RNA-
degradation step [SHARP, 1999]. And in fact the activated RISC complex is a 
classic multiple-turnover enzyme and uses siRNAs more than once 
[HUTVÁGNER & ZAMORE, 2002]. And the third part is, that siRNAs may act as 
primers on mRNA to produce, so called, “secondary siRNAs” [PLASTERK, 
2002]. The amplification step would provide an answer to the two following 
questions: How is it possible that only a small amount of dsRNA can suppress a 
much larger amount of mRNA? How comes, that the silencing effect can last for 
days, survive a lot of cell division rounds, and can be inherited to the next 
generation(s) [ZAMORE et al., 2000]? 
Suggestions implicated RNA-dependent RNA polymerases as perfect 
candidates for the amplification mechanism [BASS, 2000]. They are suggested 
to cause the development of a silencing agent and/or the amplification process 
[ZAMORE et al., 2000]. Naturally, RNA-viruses require those enzymes to 
replicate themselves by using RNA as template [SCHEPERS, 2005]. This 
implicates that they carry their own viral RNA polymerase with them. That 
explains the fact that in VIGS no RdRPs are necessary [MELLO & CONTE JR., 
2004]. In C. elegans, aberrant transgenic and viral RNAs are recognized by 
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RdRP enzymes, used as templates to replicate new siRNAs, and afterwards to 
guide the sequence-specific degradation [AGRAWAL et al., 2003]. Four 
different genes, homologous to RdRPs, were found in C. elegans: ego-1, rrf-1, 
rrf-2, and rrf-3 [SIJEN et al., 2001]. First suggestions implicated an equal 
function for ego-1 and rrf-1. The only difference would have been the 
employment in different tissues [TIJSTERMAN et al., 2002]. Now, a RRF-1 
complex is proved to be the main player for RdRP activity and therefore 
responsible for the synthesis of secondary siRNAs [AOKI et al., 2007]. 
Homologous genes, which encode RdRP proteins, are also discovered in 
Arabidopsis t. (SDE-1/SGS2) and in Neurospora crassa (QDE) [COGONI & 
MACINO, 2000]. It appears that different strategies for the synthesis of 
secondary siRNAs are used in the different tissues and also in different 
organisms [AOKI et al., 2007]. Nowadays, evidence displayed the requirement 
of RdRPs in the RNAi phenomenon in Neurospora c., Arabidopsis t., and C. 
elegans. But no closely related genes are found to encode RdRPs in humans or 
fruit flies [HUTVÁGNER & ZAMORE, 2002]. Those results go hand in hand with 
the fact that the RNAi effect in human cells is transitory. After a single injection, 
the effect abolishes after 4 to 6 days, because of the lack of an amplification 
step [ZAMORE, 2002].  
Several possible hypotheses are brought up to explain how RdRPs might 
amplify the signal. First, the guide-strand of siRNA might act as a primer to 
guide RdRPs to the single-stranded complementary target RNA [COGONI & 
MACINO, 2000]. Second, RdRPs could recognize products after the 
degradation step and use those to generate new silencing triggers. Third, it 
could also be possible that dsRNAs or siRNAs by themselves get replicated, 
using the same mechanism like viruses [BERNSTEIN et al., 2001]. It is now 
figured out, that single-stranded siRNAs are used as primers to synthesize new 
dsRNA by using target mRNA as templates for the RdRP replication step. 
Effectively, target mRNAs are recycled to new replicated dsRNAs [NISHIKURA, 
2001]. Inactivation of RdRPs in RdRP-mutants like ego-1 mutant leads to a 
decreased amount of siRNAs and results further in a loss of the silencing effect. 
This outcome might reflect an absolute requirement for the amplification to 
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produce enough secondary siRNAs to achieve the critical point of silence 
[ALDER et al., 2003].  
 
Fig. 16 Amplification mechanism in worms and plants
In mammals and fruitflies the antisense strand enters directly RISC to guide the mRNA degradation. In
worms and plants, the antisense strand is used first for an amplification step to generate secondary
siRNAs by binding to RdRP and used afterwards to guide the mRNA degradation.
modified from [NOVINA & SHARP, 2004] 
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4.3.4 Activation of transitive RNA interference under the generation of 
secondary small interfering RNAs 
In C. elegans, after introduction of dsRNAs, small interfering RNAs are found 
during the RNAi process, which origin definitively not from the original trigger 
dsRNA. Those siRNAs contain complementary regions outside of the initial 
trigger dsRNA and are termed secondary siRNAs [SIJEN et al., 2001]. Target 
RNAs are not targets only; instead they are employed in the amplification of the 
silencing signal. Because of that, secondary siRNAs can be seen as co-
products of the mRNA degradation [TIJSTERMAN et al., 2002]. In contrast to 
the secondary siRNAs, primary siRNAs are produced from the introduced 
trigger (dsRNA) through the cleavage step by dicer. The double-stranded 
primary siRNAs are converted into the single-stranded forms. If they cannot find 
homologous target mRNAs to basepair, they are going to be degraded. The 
other option is to follow their faith and get incorporated into RISC, basepair to 
target mRNA, then the amplification process could get started [PLASTERK, 
2002]. Via the degradative PCR mechanisms, the siRNAs are de novo 
generated. The antisense strand of the introduced siRNA binds to the 
complementary target RNA and primes the amplification process. After the 
synthesis, and the cleavage step by dicer, the newly secondary siRNAs are 
ready to guide the next round of target degradation, referred to as transitive 
RNAi. This results in the possibility, to target more mRNAs for degradation, and 
leads to an extended duration, and the enormous potency of the RNAi effect 
[CHI et al., 2003]. 
As already mentioned in the previous chapter, the generation of secondary 
siRNAs requires RdRPs and might be tissue-specific [PLASTERK, 2002]. The 
early suggestions that the newly synthesized secondary siRNAs run through the 
same cycle as introduced dsRNAs including the dicer cleavage step, proved not 
entirely correct. RRF-1 complex is the main factor for RdRP activity and 
generates secondary siRNAs in a dicer-independent manner. This suggestion 
derives from studies in dcr-1 deficient mutants. Secondary siRNAs are by far 
more efficient to cleave the target mRNAs than the original primary single-
stranded or double-stranded siRNAs. This discovery implicates that rather 
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secondary siRNAs than primary siRNAs are the important intermediates to 
degrade the target during RNAi in C. elegans. It seems that the secret is the 
activation of the slicer activity by the argonaute protein CSR-1. It is suggested 
that secondary siRNAs and CSR-1 form a secondary RISC with a higher 
efficiency to degrade the target [AOKI et al., 2007]. Suggestions indicated that 
in C. elegans the newly, in the cytoplasm synthesized, secondary siRNAs have 
to be transported via NRDE-3 into the nucleus, where the RNAi occurs in C. 
elegans [FISCHER, 2010].  
Because of their own characteristics, the secondary siRNAs are a new type of 
small RNAs. Secondary siRNAs contain a triphosphate group on the 5’ end, are 
always accumulated as the antisense strand, and do not have the characteristic 
5’-monophosphate group of the dicer cleavage. The 3’ end formation of the new 
type of small RNAs remains to be discovered [FISCHER, 2010]. It is also still 
unclear if secondary siRNAs participate in other biochemical reactions [AOKI et 
al., 2007]. One of the consequences of the generation of secondary siRNAs is 
the spreading effect [CHI et al., 2003]. 
The first time, transitive silencing was observed, was in C. elegans cell cultures, 
it was also displayed in C. elegans in vivo, and later on in plants as well [CHI et 
al., 2003] [AHLQUIST, 2002]. Transitive RNAi is not restricted to transgene 
targets, it can also silence endogenous gene expression [SIJEN et al., 2001]. In 
rrf-1 mutant nematodes, transient RNAi is displayed in germline cells, but 
completely inactive in somatic cells [NISHIKURA, 2001]. In rrf-1 mutant animals, 
the secondary siRNA production is blocked, which further results in no 
activation of the transitive silencing pathway [AHLQUIST, 2002]. Due to fact that 
no RdRPs are carried in mammalian and Drosophila genomes, no secondary 
siRNAs can be generated and as a result no transitive RNAi effect can be 
generated [ALDER et al., 2003]. One disadvantage might be, that the de novo 
synthesized siRNAs could target also other mRNAs than the original ones and 
induce through those side effects [DUDLEY et al., 2005].  
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4.3.5 Genes required for RNAi in Caenorhabditis elegans 
One of the first identified mutants regarding the RNAi pathway were mutations 
in the rde-1 through rde-4 genes [BOSHER & LABOUESSE, 2000]. Rde-1 and 
rde-4 mutants (rde stands for RNAi deficient) lack an RNA interference 
response, but no other defects or visible phenotypes can be scored. Under 
laboratory conditions, those mutants are fertile, healthy, and grow without any 
other deficiencies [TABARA et al., 1999]. Researchers found that rde-4 and rde-
1 are required in the inheritance step of the silencing signal though the 
formation of a hereditary agent, which results in transitive RNAi [GRISHOK et 
al., 2000]. Important is, that rde-1 is only required for the formation of the agent 
and not necessary for the actual silencing effect [TUSCHL, 2001]. So rde-1 and 
rde-4 are the initiators for the silencing effect, while rde-2 and mut-7 work 
downstream as the effectors of the response, via targeting the specific mRNAs 
for the silencing phenomena in the progeny [GRISHOK et al., 2000]. It seems, 
that rde-1 and rde-4 were the only two genes essential for the RNAi response in 
all tissues, somatic and germline, of the worm [SIJEN et al., 2001]. This 
assumption is based on the fact, that rde-1 mutants are deficient in RNA 
interference in the soma as well as in the germline [BERNSTEIN et al., 2001]. 
The requirement of RDE-1, RDE-4 and the later mentioned RRF-1 for dsRNA-
mediated interfering effect is now established [CERUTTI, 2003]. 
Rde-1 is a gene highly conserved in organisms varying from plants to 
vertebrates and is nowadays counted as member of the big argonaute family 
[TABARA et al., 1999]. Rde-1 contains the typical structure for the argonaute 
family, the PPD domain. At the N-terminal the PAZ domain and on the C-
terminal the PIWI domain is located [NYKÄNEN et al., 2001]. It is proved, that 
argonaute proteins play a key role in the RNAi mechanism and in related 
silencing phenomena. They are implicated in networking with siRNAs and in 
formation of different effector complexes such as RISC and miRNP [KIM, 2005]. 
Those two domains, PAZ and PIWI, interact also with the characteristic 3’ and 
5’ ends of the siRNAs. The PIWI domain is implicated to possess slicer 
characteristics (RNA cleavage) like the related RNase H. This slicer activity 
might get activated during the base pairing event from siRNA with the target 
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mRNA. The genome of C. elegans encodes 24 members of the argonaute 
proteins. Some are predicted like rde-1 to possess the slicer activity, some 
seem to display effectiveness for some certain siRNAs, and others might be 
employed in other biochemical reactions of the organism [FISCHER, 2010]. 
Homologous of rde-1 are found in Arabidopsis t. referred to as Ago-1, qde-2 in 
Neurospora crassa, and sting in Drosophila [DUDLEY et al., 2005] [TABARA et 
al., 1999]. It seems that rde-1 is a gene essential for RNAi, but is not required 
for other essential function in the organism [TABARA et al., 1999]. Mutations of 
homologous of rde-1, alg-1, and alg-2 have shown developmental 
abnormalities. This results from the fact, that those two genes are required for 
the function of lin-4 and let-7 [GRISHOK et al., 2001]. 
Rde-4 expresses a dsRNA binding protein, which forms a complex with dicer 
protein. In rde-4 mutants, no production of siRNAs was visible. In fact, rde-4 is 
employed in the generation of siRNAs through the cleavage of dicer via 
recognition of the trigger dsRNA. A homologous gene to rde-4 was found in the 
Drosophila RNA binding protein R2D2. Also R2D2 is found in a complex with 
DRC-1 and it is proved to be essential for RNAi. The differences are that R2D2 
is required to bind instead of the injected dsRNA, siRNAs, and incorporate them 
afterwards into the RISC complex [GRISHOK, 2005a]. 
Rde-1, rde-3, and rde-4 mutant strains lack completely in expressing an RNAi 
effect, while it seems that alterations in rde-2 do not always result in a non-
silencing outcome. If genes are targeted, which are expressed in germline, no 
RNAi response is displayed, but somatically encoded targets are sensitive to 
RNA interference and silencing can be triggered [TIJSTERMAN et al., 2002]. 
Interestingly, rde-1 and rde-4 mutants only lack an RNAi response, but are not 
defective for co-suppression or transposon silencing. But alterations of rde-2, 
rde-3, mut-2, mut-7, mut-8, and mut-9 are defective in both, RNAi and co-
suppression [TUSCHL, 2001]. 
Some mutations found to be employed in transposon silencing. Mut-2, mut-7, 
(mut stays for transposon-silencing mutants) rde-2, and rde-3 exhibit an 
increased mobilization of transposons in germline, while they show a reduced 
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RNAi response. Also mut-6 animals are implicated into mobilization of 
transposons as well. In contrast to mut-2 and mut-7 strains, mut-6 strains are 
only able to mobilize Tc1 transposons. Those results indicate a connection 
between the RNAi and the transposon silencing pathways [TABARA et al., 
1999]. Here, the mutations in rde-2, rde-3, and mut-7 display also other 
phenotypes than the mentioned ones. They show a decreased fertility, a 
temperature-dependent sterility, and a higher rate of newborn males 
[GRISHOK, 2005a]. It was discovered that some mut-strains can display a rde-
phenotype and the opposite around [KETTING & PLASTERK, 2000]. For 
example, mut-2 and mut-7, those two germline specific genes display a 
significant lack of RNAi response, compared to mut-6, a strain where efficient 
RNAi can be triggered [TABARA et al., 1999]. 
Four members of RdRP-like genes were found in C. elegans, ego-1, rrf-1, rrf-2, 
and rrf-3. Ego-1 and rrf-1 are closely linked genes [SIJEN et al., 2001]. For an 
efficient RNAi response in C. elegans ego-1 and rrf-1 are required. This fact 
results from experiments, that displayed that alterations in those two genes lost 
the possibility for RNAi in both, somatically and germline expressed genes 
[SIMMER et al., 2003]. Further research distinguished between those two. 
There was no evidence for any employment of ego-1 during RNAi in somatic 
cells [NISHIKURA, 2001]. It was figured out, that EGO-1 is employed in the 
RNAi response in the germline and for the somatic RNAi response RRF-1 is 
responsible. So it seems that ego-1 and rrf-1 are complementing each other 
[GRISHOK, 2005b]. This in fact is very useful to identify genes working either in 
somatic tissue or in the germline [GOLDEN & O'CONNELL, 2007]. Only 
recently it was found, that there is no amplification mechanism of siRNAs and 
further no transitive RNAi is displayed in rrf-1-mutants [FISCHER, 2010]. A 
homologous of ego-1 is found in qde-1 in Neurospora crassa and sde1 in 
Arabidopsis thaliana. These findings also prove the relationship of the three 
different phenomena, PTGS, RNAi, and quelling [COGONI & MACINO, 2000]. 
No functions for rrf-2 in the RNAi pathway were found [SIMMER et al., 2003]. 
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Another important mutation for the RNA interference effect is the alteration in 
the gene rrf-3 [SIMMER et al., 2003]. Alterations in rrf-3 enhance the sensitivity 
to RNAi in the animal compared to the wild-type. This results in stronger 
phenotypes, which are sometimes closely looking like a null-phenotype. Also an 
advantage is, by using the rrf-3 mutated strain, that phenotypes for some genes 
in neuronal tissue are possible [SIMMER et al., 2002]. It got also possible to 
observe phenotypes, in the hypersensitive rrf-3 strain, which were easily 
overlooked in the wild-type, because the phenotype was hardly visible 
[SIMMER et al., 2003]. Some side effects of the rrf-3 strain are the high birth-
rate of males, the sensitivity of the worms to temperature, and the decreased 
number of progeny, because of failures in the spermatogenesis [SIMMER et al., 
2002] [STEPHENS et al., 2005]. It occurred that rrf-3 is able to synergy with 
some active genes in the germline [STEPHENS et al., 2005]. 
Additional to the enhancing rrf-3 strain, 19 different eri genes (eri stands for 
enhanced RNAi) were found [GRISHOK, 2005b]. Eri-1, the strongest one, is 
suggested to enhance RNAi by increased sensitivity to siRNAs. An increased 
accumulation of the dicer products in eri-1 mutants was shown, compared to 
wild-type worms. ERI-1 is mainly a cytoplasmic protein, and is especially 
encoded in the gonads and in parts of neurons. This would explain the fact, why 
the neuronal tissue hardly responds with RNAi after the introduction of the 
trigger dsRNA. It seems that the exonuclease protein ERI-1 blocks the silencing 
by increasing the stability of the duplex structure and the degradation of the 3’ 
overhang of the siRNAs. Without the characteristic structure, siRNAs cannot 
enter RISC to guide the cleavage of the target mRNAs. Eri-1 might be one 
regulation factor for the silencing phenomenon, but it is not clear, if the 
regulation is limited to particular cell types or if eri-1 regulates the whole RNAi 
machinery in all tissues [KENNEDY et al., 2004]. Also in LIN-15B, a protein, 
enhancing the RNAi effect was found. Especially hypersensitive for RNAi is the 
eri-1 and lin-15B double mutation. In that strain, it is possible to achieve results 
in genes encoded in neuronal tissue. Because of that, this mutated strain is 
used for large-scale screens for genes with neuronal functions [JOHNSON et 
al., 2009]. 
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Sid stands for systemic RNAi-deficient loci, which means that animals with 
mutations in those genes cannot display the earlier mentioned systemic effect. 
Alterations in sid-1 result only in the lack of the spreading effect, no other 
obvious phenotypes can be seen, and the fertility seems to be normal. Sid-1 is 
expressed in RNAi sensitive cells and is employed in the transport of the signal 
from the place of the original uptake to other tissues and into the worm’s 
progeny. SID-1 is a transmembrane protein, mainly located in the cell periphery, 
and implicated into the import and export of the silencing signal. It might work 
as a channel for either dsRNA, siRNA, or some other still unknown silencing 
signals [WINSTON et al., 2002]. As mentioned before, neuronal tissue is often 
totally and often partly noncompliant to the silencing effect. It might be possible, 
that most of the neurons lack the RNAi response, because of the absence of 
the transporter SID-1 [JOHNSON et al., 2009]. Other genes implicated in RNAi 
in C. elegans are rsd (stands for spreading defective) mutants. Different rsd 
genes were found. Two independent groups worked on spreading deficient 
RNAi mutations. One group published RSD-8, a transmembrane protein, 
suggested to act as channel or receptor. The other group identified RSD-8 as 
SID-1. Results indicated that mutants of rsd-4 and rsd-8 have no cellular uptake 
of dsRNA into the animal. Compared to those two, rsd-2, rsd-3, and rsd-6, are 
able to uptake the dsRNA from the gut into somatic cells, but lack in the further 
distribution of the trigger into the germline [TIJSTERMAN et al., 2004].  
 
4.4 Practical aspects and methods of RNAi in Caenorhabditis elegans  
There are four possible ways to induce an RNAi effect in the nematode C. 
elegans; first, by injection of dsRNA into the worm; second, by feeding bacteria 
expressing dsRNA; third, by soaking them with a concentrated dsRNA solution; 
and fourth, by in vitro transcription of dsRNA from transgene promoters 
[ZAMORE, 2001] [TIMMONS et al., 2003]. 
86 
  
 
For a long time, it seemed that soaking and feeding results in weaker RNAi 
responses than with injection, but with supplementations in the food or with 
other modifications, equivalent RNAi responses can be achieved [KUMABARA 
& COULSON, 2000] [MAEDA et al., 2001]. In general, certain factors can 
influence the outcome of the phenotype, such as the choice of the sequence, 
delivery method of dsRNA, the developmental stage at which the treatment 
started, the temperature, and the stability of the target mRNA, including the 
stability of the expressed proteins [MAINE, 2001]. 
To summarize, all methods are potent to induce a visible RNAi response, but 
they all have key differences. So, it is clear that there is never just one golden 
approach for all experiments. All of these four tools should be seen as 
complement to each other, and not as a replacement of the previously invented 
method [KAMATH et al., 2000]. The ideal method depends always on the 
approach, the design of the experiment, and especially on the targeted gene. 
For smaller amounts of worms or for example, maternally encoded genes, 
soaking or injection are the methods of choice. For high-throughput screens, or 
approaches which require a large number of treated nematodes, soaking and 
feeding are amenable [FRASER & AHRINGER, 2003]. For silencing at a 
specific developmental stage, feeding and soaking are recommended. To 
achieve efficiency silencing in late larval stages, feeding nematodes with 
Fig. 17 The four possible methods for RNA transfection
aǀ Microinjection of in vitro synthezised dsRNA  
bǀ Soaking into a dsRNA solution  
cǀ Feeding of dsRNA expressing bacteria  
dǀ in vivo transcription of transgene [SUGIMOTO, 2005] 
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dsRNA expressing E. coli bacteria is recommended. Also for assays, 
investigating the longevity or behavior, feeding is the method of choice 
[SUGIMOTO, 2004]. Soaking displays in some cases stronger phenotypes than 
feeding. This can be utilized, especially in phenotypes, which are only hardly 
visible using the feeding method [JOHNSON et al., 2009]. It should not be 
overseen that soaking and feeding are methods which are easy to perform and 
no special skills are needed. Compared to injection where the scientist has to 
learn how to inject the dsRNA into the nematode without hurting or killing the 
worm [GOLDEN & O'CONNELL, 2007]. The transgene based delivery method 
is not amenable for high-throughput approaches, because the design of the 
transgenic strains requires multiple steps for each target [SUGIMOTO, 2004]. 
 
4.4.1 Microinjection 
One possibility to induce RNAi in C. elegans is by microinjection of dsRNA. The 
spreading effect is a big help for microinjection into C. elegans. It makes it 
possible, that the injection can take place at every site of the animal. Even when 
the target gene is expressed in another tissue further away, dsRNA is delivered 
into that place [TABARA et al., 1998]. Also for the inheritance effect into the 
next generation, the injection site is not crucial at all. All three ways, adult 
germline, large intestinal cells or body cavity have no influence on the efficiency 
of the RNAi response and are equally effective [HUNTER, 1999]. This offers a 
very good method to study gene functions in embryos and different genes, 
required for early development of the nematode [FRASER & AHRINGER, 
2003]. 
Usually, the injections are executed in older, larger animals like larvae in stage 
4 (L4) or in young adults, to score the phenotypes in the progeny. It displays 
stronger phenotypes, particularly in early expressed genes, with their function in 
germline development and embryogenesis [GOLDEN & O'CONNELL, 2007]. 
Another reason for the use of bigger animals is the easier performance of the 
injection into them, than into younger and smaller ones [AHRINGER, 2006]. The 
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usual injection sites are the intestinal tract or into one arm of the gonads in 
hermaphrodites. This generates enough interfering response to target most of 
the interested genes in the cells of the gonads and also in other tissues of the 
animal [SCHEPERS, 2005]. Typically, animals should be moved to a new petri-
plate to observe the progeny. In general, the phenotypes can be scored 12 to 
24 hours after the injection. It is normal, that the offspring laid during the first 24 
hours displays not the strongest effects, but after that, phenotypes should 
display more intense interfering response [GOLDEN & O'CONNELL, 2007]. An 
effective silencing is displayed in early larval stages of hermaphrodites of the 
infected progeny, while the adults displayed already an initial recovery of the 
interference effect. This might be explained by the fact of dilution of the initial 
trigger by cell division [TIMMONS et al., 2001]. Genes, which are expressed 
more than one time during the development, must be targeted in every single 
developmental stage to reduce the gene products [MAINE, 2001].  
Microinjection was the first invented method for dsRNA delivery [STEPHENS et 
al., 2005]. Some limitations occur with this method, which have to be calculated 
in the design of every approach. It is the most labor intensive method, a lot of 
equipment is required, and certainly not the method of choice for researchers 
starting with RNAi experiments in C. elegans [SCHEPERS, 2005]. It takes some 
time to learn the procedure. To infect 10 to 30 hermaphrodites, around half an 
hour is needed; every individual animal has to be injected one after each other. 
So the whole process is not adaptable for large groups, large-scale, or whole-
genome screens [FRASER & AHRINGER, 2003]. Typically, only one to ten 
nematodes are treated by the microinjection-method per experiment 
[JOHNSON et al.,  2009]. It is believed, that injection of dsRNA into C. elegans 
is the most effective way to generate an interference response [HUNTER, 
1999].  
 
89 
  
4.4.2 Feeding of dsRNA expressing bacteria 
It was figured out, that not only injection of double-stranded RNA into the animal 
results in an RNAi response; also the possibility of feeding dsRNA is given. In 
general, not naked dsRNA is used as food source, especially generated E. coli 
bacteria, which expresses the corresponding dsRNA of the gene of interest in 
the host organism, serves as food source on agar plates [HUNTER, 1999]. The 
phenotypes are scored either in the treated nematode or in the F1 generation 
[JOHNSON et al., 2009].  
For a long time, researchers were not of the same opinion about the 
effectiveness of the feeding method, compared with the injection method. Some 
researchers postulate the feeding method as less effective than direct 
microinjection [TIMMONS & FIRE, 1998]. The silencing response is especially 
less powerful during development of late embryonic and early larval stages, but 
potent to trigger gene silencing in adults and early embryos [TIMMONS et al., 
2001]. The idea arose, that it might be possible that with starting the treatment 
earlier, the animals are exposed for a longer period of time, and this limitation 
might be overcome. Those treated worms exhibit phenotypes at least as strong 
as phenotypes of nematodes treated with direct injection, and it is as sensitive 
as gene silencing by dsRNA injection. Exclusive the nervous system, nerve 
cells respond only hardly with a silencing effect [KAMATH et al., 2000]. Also 
continuous feeding, results in a more potent outcome of the silencing effect in 
postembryonic phenotypes [FRASER & AHRINGER, 2003]. 
It was also figured out that the feeding method might be gender-specific. Males 
(him-strains) appeared to have a decreased uptake of dsRNA compared to 
hermaphrodites. It can be seen in the results, that males are less affected by 
RNAi. The explanation might be simple, males are not eating that much; or 
could be more complex, that indeed the gender has influence on the dsRNA 
uptake from the food source, or even on the RNAi mechanisms, or its 
components itself are responsible [TIMMONS et al., 2001]. 
There are some advantages of this method over the injection. The feeding is a 
method far less labor intense, easy to use, most inexpensive compared with 
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injection or soaking, no special equipment is required, it is amenable for a large 
number (thousands) of worms at the same time, and in a short time period 
possible to test a large number of various genes at the same time, genome-
wide analysis are amenable, and it is used to detect genes participating in the 
RNAi mechanism itself [KAMATH et al., 2000]. Another positive effect is the 
possibility to feed at every developmental stage. So the down-regulation of the 
target is obvious in every favored stage [GOLDEN & O'CONNELL, 2007]. One 
drawback, which is also an advantage too, is the design of the E. coli bacteria to 
express the corresponding dsRNA to the target gene. It is quite an amount of 
work to clone the desired DNA structure into a transport plasmid vector and 
transform it into the specific E. coli. On the other hand, once the strain is 
generated, it is possible to reuse it and replicate it for very little cost [KAMATH & 
AHRINGER, 2003]. Libraries of the designed E. coli strains are developed, 
containing 16,757 bacterial strains. This means, 86% of the back then predicted 
19,427 genes of C. elegans are covered [KAMATH et al., 2003]. To execute an 
RNAi experiment by feeding the ready-made, commercially available E. coli 
strains, is a very easy method to perform, also for beginners in this field 
[JOHNSON et al., 2009]. Only through the development of the RNAi feeding-
libraries, gene identifications regarding chromosome morphogenesis, lifespan, 
nucleotide excision repair, fat storage, and transposon silencing became 
possible [STEPHENS et al., 2005]. 
For the plasmid design, there are two different possibilities. Either a single 
fragment of the sequence of interest is cloned into a vector, flanked by two T7 
polymerase promoters, called bi-directional promoter configuration, or a hairpin 
structure is designed with a single T7 promoter and an inverted repeat structure 
broken up by a non-homologous sequence [TIMMONS et al., 2001]. In the host, 
double-stranded RNA will be expressed, further processed by dicer into 
siRNAs, and after the cleavage step the siRNAs will guide the target mRNA 
degradation [SCHEPERS, 2005].  
Important facts to consider before starting the experiment are first, the starting 
point of the first exposure to the dsRNA-containing food. Recommended is the 
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use of L1 larvae, to achieve the longest exposure time, but certainly it depends 
also on the gene that should be silenced. Second, there should be some tests 
on the temperature before starting, because the temperature can have a great 
influence on the resulting phenotypes [SCHEPERS, 2005]. Low temperature is 
recommended, so bacteria cannot find their optimal living conditions. Third, 
whether the liquid culture or the culture using agar plates is preferred. 
Thousands of nematodes can be cultured on RNAi plates, but millions of worms 
can be grown in liquid culture. The difference is that the expressed phenotypes 
are more visible on agar plates. Fourth, to avoid contaminations, plates as well 
as liquid cultures should be supplemented with carbenicillium. Worms favor 
eating the contaminant instead of the bacterial strains, Escherichia coli strain 
HT115, bearing the dsRNA [JOHNSON et al., 2009]. 
 
4.4.3 Soaking of Caenorhabditis elegans in dsRNA solution 
Soaking nematodes in a dsRNA solution proved also to be an effective method 
to induce RNA interference [BOSHER & LABOUESSE, 2000]. The worms are 
soaked for 24 hours in a high concentrated dsRNA solution without any other 
food source. After this process, the worms are transferred to agar plates to 
recover. Now, the phenotypes can be observed and scored [SUGIMOTO, 
2004]. It should be mentioned that the silencing effect, based on the soaking 
method, is dependent on the concentration. The minimum concentrations to 
produce a visible phenotype are variable and depend on the targeted gene itself 
[SUGIMOTO, 2005]. In general, soaking the nematodes in the high-
concentrated dsRNA (1-5mg/ml / 24h) solution can be performed at any 
developmental stage. Results in the changed phenotypes can be counted in the 
parent generation as well as in the progeny [FRASER & AHRINGER, 2003]. It is 
suggested that the intake of dsRNA occurs though the pharynx. With 
supplementation of serotonin, the pharyngeal pumping can be stimulated, which 
is possible, but not required [JOHNSON et al., 2009]. Soaking was also 
believed to be not equally potent as microinjection. But it was figured out later, 
that with supplementation of spermidine into the dsRNA solution, the potency 
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and reproducibility is significantly improved. The method is effective for targets 
employed in early embryogenesis, germline development, and muscle function. 
As mentioned earlier, soaking is not potent enough to efficiently induce 
silencing in nervous cells [SCHERER & ROSSI, 2005]. 
Advantages of the feeding and soaking methods are that younger nematodes in 
their larvae stages 1 to 4 can already be used, for microinjection they would be 
too small [MAINE, 2001]. Soaking is by far not that labor-intensive as 
microinjection and less time-consuming [MAEDA et al., 2001]. It is easy to 
perform and no special equipment is needed [SUGIMOTO, 2005]. Usually, 
between 10 and 100 worms are treated per experiment. With the development 
of dsRNA libraries, high-throughput analysis became approachable [JOHNSON 
et al., 2009]. It is a great method to investigate genes, which play multiple roles, 
and which are expressed in more than one developmental stage [SUGIMOTO, 
2005]. A huge disadvantage is the high cost and amount of time for the large 
amount of in vitro synthesized and purified double-stranded RNA. Another 
drawback is that the exposure time is limited [GOLDEN & O'CONNELL, 2007]. 
And it could be possible that the worms get intoxicated by the treatment 
[JOHNSON et al., 2009]. Several groups in different labors performed analysis 
via soaking nematodes in dsRNA. The results were largely consistent, but there 
were some in-coherences as well. This might be explained by different 
definitions of phenotypes and different culture conditions [SUGIMOTO, 2005]. 
Depending at the developmental stage, in which the gene of interest is 
expressed, there are different approaches to reach the gene knock-down. To 
silence genes employed in early embryogenesis, L4 worms are soaked for 24 
hours. Over the period of time, the larvae grow into adults, but the oogenesis 
stays in the initial condition, and it seems that the RNAi effect is executed 
during this time [SUGIMOTO, 2005]. For detecting genes function in 
embryogenesis and post-embryonic development silencing, the soaking method 
is ideal. L1 larvae are soaked. During the period of soaking there occurs no 
development, the L1 stays arrested, but the silencing continues. In contrast, 
93 
  
injection or soaking of L4 worms results in embryonic lethality and as a result no 
post-embryonic phenotypes can be scored [MAEDA et al., 2001].  
 
4.4.4 Multiple gene interactions 
Experiments proved that multiple gene interactions are not very feasible. 
Feeding bacteria expressing two different genes resulted in a significant 
reduced displayed phenotype of both genes [KAMATH et al., 2000]. The 
approach to target multiple genes in one approach displayed even weaker 
phenotypes, than when two genes were silenced at the same time [JOHNSON 
et al., 2009]. 
 
4.5 Knockout of the reduced folate carrier 
Folate is an essential water-soluble B-vitamin, which cannot be synthesized by 
humans. As a result, humans and other mammals as well, are dependent on 
exogenous sources of the vitamin. It is employed in the normal cell function and 
development of the organism. Deficiency of folate leads to various deficiency 
symptoms, such as megaloblastic anemia, growth retardation, and neurological 
disorders [BALAMURUGAN et al., 2007]. Supplementation of folate during 
pregnancy is highly recommended to prevent neural tube defects. It was figured 
out, that reduced folate carrier (RFC) in humans (hRFC) is responsible for the 
folate uptake, additional to folate receptors, and the proton coupled folate 
transporter [AUSTIN et al., 2010]. Surprisingly, two orthologs of the hRFC were 
found in the nematode C. elegans, called folt-1 and folt-2, which share a 40% 
and a 30% identity. RNA interference proved now the existence of an active 
folate-uptake system through folt-1 in the worm [BALAMURUGAN et al., 2007]. 
94 
  
Folt-1 encodes an around 46.5kDA heavy protein, composed out of 410 amino 
acids and ten transmembrane domains, including a loop between the 
transmembrane domain 5 and 6 of about 58 amino acids. Folt-1 is differentially 
expressed in the tissues. The highest level is seen in the pharynx and the 
intestine of the nematode. Suggestions implicate the intestine to secret different 
kinds of digestive enzymes, which further lead to the assumption that the 
intestine is involved in the folate uptake of C. elegans. Folt-1 proved to be Na+-
independent, but displayed a higher activity rate at a pH of 5.5 than at 7.4. 
Evidence displayed the sensitivity to anti-inflammatory agent sulfasalazine as 
well as to the anion transport inhibitors DIDS and SITS [BALAMURUGAN et al., 
2007]. C. elegans knockout mutations displayed a significant inhibition of folate 
uptake, which seems to lead to infertility through defects in germline 
proliferation, decreased life span and metabolism, and defective oogenesis in 
hermaphrodites. Additional in males, a decreased production of sperm is 
displayed. Those effects can be seen universally and are not limited to C. 
elegans. In mice embryos and Drosophila melanogaster, a lack of folate results 
in embryonic lethality. And as mentioned before, folate deficiency in humans 
during pregnancy can lead to neural tube defect [AUSTIN et al., 2010].    
Fig. 18 Predicted structure of the folt-1 protein
modified from [BALAMURUGAN et al., 2007] 
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5. Conclusion 
After a year, reading and writing about the RNAi mechanisms, I am absolutely 
the same opinion as A. Fire and C. Mello; RNA interference is a very powerful 
tool. And Andy Fire and Craig Mello knew that they discovered something 
incredible, but they had no idea how incredible it really was [MELLO, 2007]. 
Despite all the mentioned pros and contras, including the side-effects and off-
target effects, RNA interference is a very potent and specificity mechanism. I 
am confident, that all those problems like the stability of the silencing agent, 
modifications of the agent, sufficient uptake of the lowest possible dose, and the 
activation of one arm of the immune system, can be overcome with a lot of 
research.  
The expectations and hopes for the development of novel drugs and individual 
gene therapy are still very high, but every method is shadowed with drawbacks 
[TUSCHL & BORKHARDT, 2002]. In my opinion, the biggest concern is the 
usage of the RNA interference as a therapeutic tool. Through using this 
mechanism, the natural system gets hijacked. It might be possible that the 
endogenous function may work not with its fully capacity which could result in 
an insufficient endogenous response and further might displays, still unknown, 
unwanted side-effects [SHAN, 2010]. This problem has to be investigated more 
rigorous, before any applications as treatments can get started.  
I would like to finish with the words, quoting C. Mello:  
„I think we almost always underestimate the complexity of life and of 
nature” [MELLO, 2007]. 
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V. SUMMARY 
RNAi is a gene silencing mechanism; two decades ago, Craig Mello and 
Andrew Fire discovered the knock-down phenomenon in C. elegans. In general 
the mechanism starts by cleavage of long double-stranded RNA by the RNase 
III enzyme dicer into 21-25nt long small interfering RNAs. After the activation of 
the RISC complex through ATP and the recognition of the small interfering 
RNA, the double-strand gets unwind by a helicase. The strand with the lower 
thermodynamic stability at the 5’-end enters RISC (typically the antisense 
strand) while the other one (the sense strand), gets degraded. By perfect 
complementarities of the target mRNA and the siRNA, the target gets cleaved 
and destroyed, in contrast to imperfect complementarity, where siRNA works 
like microRNA and results in an translational repression by binding to the 3’UTR 
region of the target mRNA.  
Some specialties like the systemic effect, the inheritance, the transitive 
character, and the generation of secondary siRNA appear not in every 
organism. Mammals and Drosophila melanogaster lack the mechanism to 
generate secondary siRNAs. This depends on the missing homologous of 
RdRP enzymes, and results in the transient effect of RNAi in mammals. The 
spreading mechanism is established in plants, planarias, and C. elegans, but 
not in flies or mammals. This is based on the fact, that in those two organisms, 
homologous of rsd or sid are missing. 
RNA interference is next to the gene silencing mechanism involved in different 
natural functions such as heterochromatin modification and methylation, 
transposon silencing, works in lower organisms as an ancient defense system, 
and can induce an immune response in mammals. This results in the activation 
of the PKR pathway and the activation of the 2’-5’ oligoadenylate synthase. This 
fact, as well as the possibility to induce off-target effects and cross interference, 
complicates the development of therapeutic agents. 
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VI. ZUSAMMENFASSUNG 
RNA Interferenz ist ein Mechanismus zur Gen-Abschaltung. Vor etwa 20 Jahren 
entdeckten C. Mello und A. Fire dieses „knock-down“ Phänomen in C. elegans. 
Generell startet der Mechanismus mit dem Spalten von einem langen, 
doppelsträngigen DNA-Molekül durch Dicer, ein RNase III Enzym, in lauter 
Bruchstücke (small interfering RNAs) von einer Länge von 21 bis 25nt. Der 
RISC-Komplex muss mithilfe von ATP aktiviert werden, erst danach wird das 
doppelsträngige RNA-Molekül an den Komplex gebunden und durch eine 
Helicase in Einzelstränge aufgespalten. Üblicherweise wird der Strang mit der 
geringeren thermischen Stabilität am 5‘ Ende an RISC gebunden (antisense) 
und der andere wird abgebaut (sense). Ist das Fragment mit der Ziel-RNA 
komplementär, wird dieses durch Spaltung zerstört, bei einer partiellen 
Komplementarität kommt es zu keiner Spaltung, sondern zu einer Hemmung 
der Translation. 
Manche Besonderheiten wie der systemische Effekt, die Vererbbarkeit des 
Interferenz-Signals, die Möglichkeit zur Vervielfältigung des Signals und die 
Produktion von secondary siRNA sind nicht in jedem Organismus gegeben. In 
Säugetieren und Drosophila melanogaster können keine secondary siRNAs 
produziert werden, was auf fehlende RdRP-Enzyme zurückzuführen ist. Die 
Möglichkeit zur Signalverteilung im gesamten Organismus ist in Pflanzen, 
Planarien und C. elegans gegeben, jedoch nicht in Fliegen oder Säugetieren. 
Dies ergibt sich aus dem Fehlen von homologen rsd- und sid-Genen. 
RNA-Interferenz ist nicht nur ein Mechanismus der zur zielgerichteten 
Abschaltung von Genen genutzt werden kann, sondern besitzt zudem 
verschiedene natürliche Funktionen wie Modifikation und Methylierung von 
Heterochromatin sowie Kontrolle der Transposons. In einfacher entwickelten 
Lebewesen wirkt RNA-Interferenz als ein Abwehrsystem gegen Viren und in 
Säugetieren kann es eine Immunreaktion auslösen. Zusätzlich zur Aktivierung 
des Immunsystems erschweren auch die Möglichkeiten von off-target effects 
sowie cross-interference die Entwicklung von neuen, individuellen Gentherapien 
und Medikamenten. 
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